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Abstract 
Therapeutic monoclonal antibodies (mAbs) are a rapidly growing category of 
pharmaceutical proteins. For the recovery of mAbs from fermentation broths, protein A 
affinity chromatography is a dominant process used as a capture step to reduce harvest 
volume and remove the majority of impurities. However, protein A resin is highly 
expensive. Therefore, biopharmaceutical industry also tries to find new non-
chromatographic techniques to replace protein A chromatography and thus to meet the 
ever-increasing market of therapeutic mAbs. 
     The objective of this PhD thesis is to explore the possibility of implement 
crystallization in the early downstream process for the recovery of monoclonal antibody 
conforming to GMP requirements. A detailed phase diagram, which is required for the 
control of crystallization process, was established for an intact mAb after identifying 
crystallization conditions. Conditions were adapted to crystallize the antibody directly 
from concentrated clarified cell culture supernatant. The purification efficiency in a single 
crystallization step was similar to that of protein A chromatography, though with lower 
yield and a long incubation time. The crystallization rate and crystal yield of mAb were 
determined in the presence of various model contaminating proteins. The spiking proteins 
exhibited different impacts on the crystallization of target mAb. Light scattering 
experiments indicated that this protein-specific difference may be related to the sign of the 
protein surface charge, where proteins with uneven charge sign as target protein had 
stronger influence on crystallization process than proteins with the same sign due to 
electrostatic interactions. The results also suggest interaction analysis as a useful tool to 
predict whether a specific contaminating protein will have adverse effects on 
crystallization and should help in the future to develop methods overcoming those adverse 
effects. 
     In addition, since amorphous aggregates compete with the formation of crystals, 
stabilization potency of different osmolyte classes (polyols, amino acids and methylamine 
groups) was examined focusing on hen egg white lysozyme as an example of a folded 
globular protein. It was found that polyols increased both thermal and kinetic stability in a 
concentration-dependent manner, whereas most compounds from the amino acids and 
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methylamine groups led to destabilization. Furthermore, it was observed that there was 
similar but not identical effects of particular osmolytes on both types of stability. Kinetic 
stability therefore cannot solely be predicted by thermal stability. Such information may 
help to control aggregation and thereby, benefits crystallization. 
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Zusammenfassung 
Monoklonale Antikörper (mAbs) sind eine schnell wachsende Gruppe therapeutischer 
Proteine. Die Protein A-Affinitätschromatographie ist dabei das dominierende Verfahren 
bei der Aufreinigung der mAbs aus Kulturübständen. Sie ermöglicht die Reduzierung des 
Puffer-Volumens und die Entfernung der meisten Verunreinigungen in nur einem Capture-
Schritt, das Säulenmaterial ist allerdings sehr teuer. Die biopharmazeutische Industrie 
sucht daher nach neuen, nicht-chromatographischen Verfahren, die die Protein A-
Chromatographie ersetzen und so den immer steigenden Markt von therapeutischen mAbs 
befriedigen können.  
Das vorrangige Ziel dieser Dissertation ist die Untersuchung der Möglichkeit eines GMP-
konformen Aufreinigungsprotokolls für mAbs mittels technischer Proteinkristallisation. 
Nach Ermittlung der Kristallisationsbedingung wurde ein detailliertes Phasendiagramm 
erstellt, mit dem die Kristallisation im Batch kontrolliert werden kann. Die 
Kristallisationsbedingung wurde erfolgreich auf die Kristallisation aus 
Fermentationsüberstand übertragen. Die Reinheit des mAbs nach Kristallisation war 
vergleichbar mit der nach Protein A Chromatographie, jedoch mit einer niedrigeren 
Ausbeute und einer langen Inkubationszeit. Die Wachstumsgeschwindigkeit und Ausbeute 
des mAb-Kristalls wurde in Anwesenheit von Modell-Kontaminanten (Proteine 
unterschiedlicher Größe und Ladung) bestimmt. Dabei zeigten sich erhebliche 
proteinspezifische Unterschiede. Untersuchungen mittels Lichtstreuung wiesen darauf hin, 
dass der Einfluss von Kontaminanten mit der  Oberflächenladung des Proteins korrelieren: 
Fremdproteine mit der gegengesetzten Ladung zum Zielprotein beeinflussten den  
Kristallisationsprozess stärker als solche mit gleicher Ladung. Diese Ergebnisse zeigen, 
dass die Analyse der Wechselwirkung zwischen Proteinen ein nützliches Werkzeug sein 
könnte, um ungünstige Einflüsse von Fremdproteinen auf Kristallisation vorherzusagen. 
Außerdem könnte sie bei der Entwicklung eines Verfahrens zur Beseitigung von 
nachteiligen Einflüssen hilfreich sein.  
Weil amorphe Aggregate mit der Bildung des Kristalls konkurrieren können, wurde 
anhand des globulären Modellproteins Lysozym aus Hühnereiweiß die potentiell 
stabilisierenden Effekte von unterschiedlichen Gruppen von Osmolyten (Polyole, 
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Aminosäuren, Methylamine) untersucht. Polyole erhöhten dabei sowohl die thermische als 
auch kinetische Stabilität auf konzentrationsabhängige Weise, wohingegen die meisten 
Aminosäuren und Methylamine zu einer Destabilisierung des Proteins führten. Des 
Weiteren zeigten bestimmte Osmolyte ähnliche aber nicht identisch Effekt auf beide 
Stabilitätsarten, kinetische Stabilität lässt sich daher nicht lediglich durch thermische 
Stabilität prognostizieren. Auf Basis dieser Informationen könnten die Aggregation 
kontrolliert werden, was dem Kristallisationsprozess hilfreich sein könnten.  
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Abbreviations 
AFM atomic force microscopy 
BSA bovine serum albumin 
CEX cation exchange chromatography 
CG-MALS composition-gradient multi-angle static light scattering 
CHO Chinese hamster ovary 
COS choline-O-sulfate 
CVC cross-virial coefficient 
DLR double linear regression 
DLS dynamic light scattering 
Exp. Experiments 
HCP host cell protein 
HPLC high performance liquid chromatography 
IgG4 immunoglobulin G, subclass 4 
LRV Log reduction value 
mAb monoclonal antibody 
PEG polyethylene glycol 
RT room temperature 
RI refractive index 
SEC size exclusion chromatography 
SLR single linear regression 
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SLS static light scattering 
SVC  self-virial coefficient 
ThT Thioflavin T 
TMAO trimethylamine-N-oxide 
 
Symbols 
A2 second virial coefficient 
A11 second cross virial coefficient 
adj. r
2
 adjusted correlation of determination 
c concentration 
dn/dc specific refractive index increment 
I? scattered light intensity of solution 
I?, solvent scattered light intensity of solute 
K* optical constant 
Mw weight-average molar mass 
n0 refractive index of solvent 
NA Avogadro’s number 
R(?) excess Rayleigh ration at the angle ? 
P(?) particle scattering factor 
Tm protein melting point 
V? detector signal voltage of solution from light scattering 
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V?, solvent detector signal voltage of solvent from light scattering 
Vlaser detector signal voltage of laser from light scattering 
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1 
Introduction 
 
1.1 Background 
Biopharmaceuticals are protein or nucleic acid based pharmaceutical substances used for 
therapeutic or in vivo diagnostic purposes, which are produced by means other than direct 
extraction from a native (non-engineered) biological source (Walsh G. 2003; Walsh G. 
2001). They constitute about one-third of drugs currently in development (Sekhon BS. 
2010). Currently approved biopharmaceuticals and proteins are now widely used to treat 
diseases as diverse as cancer, autoimmune disorders, myocardial infarction and various 
growth factor deficiencies (Anicetti V. 2009).  
     During the past two decades, in upstream processing cell culture densities and cellular 
productivity have been improved considerably. Fermentation runs longer than it did a 
decade ago, and protein titers have risen to several grams per liter. The advances in 
recombinant DNA, metabolic engineering and hybridoma technologies have permitted the 
large-scale production of virtually any biomolecule at increased titer through a 
fermentation route (Walsh G. 2000). However, improvements have not occurred 
correspondingly in downstream processing. Frequently, a “high product” upstream process 
cannot be matched by scaling up the downstream process correspondingly without 
increasing the specific production cost or losing yield. The downstream processing, 
therefore, has been the bottleneck in the overall production process. 
     Therapeutic monoclonal antibodies (mAbs) are a promising and rapidly growing 
category of pharmaceutical proteins. Antibody, also called immunoglobulin (Ig), plays a 
very important role in the immune system. The Igs are produced by the immune-competent 
cells and secreted by the ? lymphocytes of the immune system in response to foreign -
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proteins or macromolecules (antigens). The specific antibody-antigen interaction is widely 
used in analytical methods, such as ELISA and Western Blot. The first monoclonal 
antibody product was licensed in 1986 (Birch JR and Racher AJ. 2006). Since then, 
therapeutic monoclonal antibodies are broadly used as a major part of treatments in various 
diseases including transplantation, oncology, autoimmune, cardiovascular, and infectious 
diseases (Nissim A, Chernajovsky Y. 2008) and have become a driving force of growth in 
the biopharmaceutical industry. In 2009, mAbs maintained their ranking as the best-selling 
class of biologics, with their US sales reaching ~ $ 16.9 billion — an 8.3% growth over 
their 2008 sales (Aggarwal S. 2010). As of March 2011, 29 mAbs have been approved by 
FDA (Upreti D. 2012).  
     The majority of these commercial mAbs are produced from Chinese Hamster Ovary 
(CHO) and NS0 cells by recombinant DNA technology (Yoo EM, et al. 2002), followed by 
a sequence of filtration and column chromatography process steps. Several preparative 
modes of chromatography have been employed for the process-scale purification of mAbs 
to achieve an overall yield of about 80 %. A typical procedure is depicted in Figure 1. 
Protein A affinity chromatography, by which the mAb purity can exceed 95 %, is a 
dominant process used as a capture step to reduce harvest volume and remove the majority 
of impurities. The use of protein A chromatography has greatly simplified the recovery 
process of monoclonal antibodies. Direct capture by this step followed by ion exchange 
chromatography and size exclusion chromatography has been employed for purifying 
monoclonal antibodies from fermentation broths (Shukla AA, et al. 2007). However, 
protein A chromatography has also some drawbacks. First, protein A resin is highly 
expensive (ca. US $ 10,000 per liter), which can be several times as expensive as other 
chromatographic materials. Second, Protein A ligand may be cleaved by proteases present 
in the cell culture supernatant and become an impurity in itself. Finally, elution of mAb 
occurs at low pH, which can lead to aggregation of mAb and loss of activity. Aggregation 
usually leads to inactivation of the drug and can even trigger an immunogenic reaction in 
the organism (Arosio P, et al. 2011). Although much progress has been made to increase 
dynamic binding capacity of protein A material and make the media resistant to alkaline 
exposure damage, the media still remains expensive and sensitive to product residence 
time (Fahrner RL, et al. 2001).  
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Figure 1. A typical procedure for the recovery of mAb from cell culture. A sequence of 
chromatographic processes are used for the antibody purification.    
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     In the past decade, CEX as an alternative capture step to protein A chromatography has 
been evaluated for manufacture of monoclonal antibodies. During CEX, antibody binds to 
column media because of the positive net charge if the pH value is below its isoelectric 
point and elutes through increase of pH value or competition from increased salt 
concentration. While older CEX media were low capacity (20-30 g mAb/L), nowadays, 
CEX media can reach a dynamic binding capacity of more than 100 g/L for mAbs. 
(Urmann, et al. 2010; Lain B, et al. 2009; Jackewitz A. 2008). The progress of increased 
capacity of CEX media has made CEX a viable alternative for protein A chromatography. 
However, capacity of chromatography matrices cannot increase unlimitedly because of the 
steric hindrance of protein molecule and the absorption kinetics of the proteins to gel 
matrices. (Werner RG. 1998.). To meet the ever-increasing productivity in cell culture, for 
a long-term strategy, biopharmaceutical industry therefore tries to find new non-
chromatographic techniques or revisit older technologies with a new application (Chon JH 
and Zarbis-Papastoitsis G. 2011). Crystallization is one of such technologies to be 
considered as potential operation to meet the damands and reduce cost during production 
of mAb. 
     Crystallization is a separation and purification process widely used in chemical 
technology for the production of small molecules from bulk chemicals. For 
macromolecules such as proteins, crystallization is mostly applied in X-ray structure 
analysis. However, as one of the oldest chemical purification technologies, crystallization 
is also attracting increasing interest as a protein purification process. Many reports of 
purification of enzyme from bulk fermentation through crystallization have been published 
(Fukumoto J, et al. 1963; Kitazono A, et al. 1992; Pitts JE, et al. 1993). Several enzymes, 
such as cellulase, glucose isomerase and alcohol oxidase, have been crystallized for 
commercial production (Aehle W. 2007) A purification process of an industrial enzyme 
using crystallization is illustrated in Figure 2.  
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Figure 2. A schematic diagram for recovery of subtilisin from fermentation broth using 
crystallization (Becker T and Lawlis VB. 1991). 
 
1.2 Objective and research methodolgy         
The objective of this research is to develop a process for monoclonal antibody purification 
using crystallization. To achieve this goal, a monoclonal antibody of the immunoglobulin 
G subclass 4 (IgG 4), was employed to evaluate the feasibility of recovery of mAbs using 
crystallization as a capture or intermediate step conforming to GMP requirements. 
Different unrelated proteins were added to crystallization batches of protein-A-purified 
mAb in order to understand the influence of impurities on the crystallization process. 
Because amorphous aggregates compete with the formation of crystals, protein stability is 
a critical prerequisite for successful crystallization. Therefore, the effect of different 
osmolyte, a class of small organic molecules used by living organisms to respond to 
cellular stress, on protein stability was investigated. 
Purification of mAb by crystallization 
In Chapter 3, suitable crystallization conditions for a IgG4 type antibody BImAb04c, 
which was partially purified by protein A chromatography, were found using the sparse 
matrix and subsequently grid screen strategies. The phase diagram, which is important for 
predictive development of an efficient purification step, was determined from microbatch 
experiments. Crystallization was inspected by microscopy to distinguish amorphous 
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precipitate and crystal through birefringence. BImAb04c was then purified from culture 
supernatant through crystallization. Recovery yield and product purity from the 
crystallization process were compared to that of protein A chromatography. Different 
analytical techniques, such as UV280 absorption, SDS-PAGE and high performance size 
exclusion chromatography (HP-SEC), were applied to determine protein concentration and 
sample purity. Surface plasmon resonance spectroscopy served to verify intact Fc-binding 
activity of crystallized antibody. To meet regulatory requirements for biopharmaceuticals, 
the ability of the process to remove critical contaminants was investigated by crystallizing 
mAb in the presence of spiked bacteriophage (virus model) or genomic DNA. 
Influence of contaminating proteins on crystallization  
The presence of impurities is a critical problem in X-ray structure determination, because 
incorporation of impurities into protein crystals may affect defect densities, crystal 
morphology, crystal size, and diffraction resolution (Plomp M, et al. 2003; McPherson A, 
et al. 1996). For bulk protein crystallization, crystal quality is less important. However, 
impurities can cause undesirable interactions on the surface of growing crystals (Anderson 
WF, et al. 1988; Caylor CL, et al. 1999; Kurihara K, et al. 1999) and are often associated 
with “step pinning”, where they adsorb to the surface of a growing crystal and impede the 
addition of desired components (McPherson A, et al. 1996.; Plomp M, et al. 2003). The 
presence of impurities may affect both nucleation and growth rate of crystal and may lead 
to lower rate and yield of protein crystallization. In Chapter 4, different unrelated proteins, 
such as bovine serum albumin (BSA), lysozyme, etc., were used as model contaminants in 
spike test to investigate how protein impurities affect antibody crystallization. Since the 
crystal quality requirements are quite different for purification purposes compared to 
protein structure determination, only growth rate and recovery rate were investigated in 
this work. 
     To corroborate these results with direct interaction studies in solution, static light 
scattering was measured. Different types of interactions occur between proteins, including 
ionic, hydrophobic, van der Waals and polar interactions such as hydrogen bonds (Lodish 
H, et al. 2000). Both solvent composition and protein concentration influence the degree of 
the macromolecular interactions. The strength and direction of the interactions (repulsive 
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or attractive) can change drastically depending on buffer conditions. The overall 
interaction between molecules in dilute solution can be described by osmotic virial 
coefficients, which appear as coefficients in the osmotic pressure equation. A positive 
value reveals repulsive interaction between molecules, while a negative value suggests 
attractive interaction. A multi-angle light scattering detector (MALS) for static light 
scattering (SLS) measurement was employed in this work to study interactions between 
proteins in solution. SLS allows determining molecular weight, size and osmotic virial 
coefficients. 
     For the study of interaction between antibody and contaminating proteins, cross-virial 
coefficients A11 (CVC) were determined through composition gradient - multiangle static 
light scattering (CG-MALS). The CG-MALS technique consists of preparing solutions of 
each of the required compositions, delivering each to an SLS instrument automatically, 
recording the scattered intensity and concentration values in batch module, and analyzing 
the data through Zimm or Debye Plots (Some D, et al. 2008). In this work, monoclonal 
antibodies were mixed with different contaminating proteins at varying ratios in 
crystallization buffer, and interactions between proteins were characterized by CG-MALS. 
Effect of osmolytes on protein stability 
Protein stability is an issue of consideration in crystallization. The formation and growth of 
amorphous aggregates, which are often irreversible, competes with the formation and 
growth of crystals. Denaturation, formation of oligomers or conformational change should 
not occur or at least be minimized during the crystallization process. Storage solvents for 
proteins are optimized not only by studying the effect of pH value and ionic strength on 
protein stability, but also the effect of additives. Osmolytes, such as sugars and amino 
acids, are a class of small organic molecules used by living organisms to respond to 
cellular stress (Harries D, Rösgen J. 2008). They can influence thermal and kinetic stability 
of protein in solution resulting from volume exclusion (hard interactions), or, electrostatic-, 
hydrophobic-, and van der Waals interactions (soft interactions) (Saunders AJ, et al. 1999). 
In Chapter 5, 21 selected osmolytes from different classes (polyols, amino acids and 
methylamine groups) was chosen and their thermal and kinetic stabilizing potencies were 
determined as a function of osmolyte concentration. Thermal stability was studied by 
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recording thermal denaturation curves with differential scanning fluorimetry using SYPRO 
Orange. Kinetic stability was investigated using fibrillation of lysozyme as a model system 
for aggregation, because its kinetics can be manipulated easily by adjusting experimental 
conditions. The fluorescent dye Thioflavin T (ThT) was used to monitor fibrillation 
kinetics of lysozyme in real-time. ThT fluoresces strongly with excitation and emission 
maxima at approximately 440 and 490 nm respectively in the presence of samples 
containing ?-sheet-rich deposits (LeVine H III, 1993; Nilsson MR, 2004). It was also 
attempted to correlate thermal and kinetic effect. 
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2 
Theory 
 
2.1 Protein Crystallization 
Crystallization is a means by which a metastable supersaturated solution can reach a stable 
lower energy state by reduction of solute concentration (Weber PC. 1991.) and is widely 
used in the chemical industry for separation and purification purposes. Unlike 
crystallization of small molecules, crystallization of macromolecules such as proteins has a 
history of only about 160 years. The first published observation of the crystallization of 
hemoglobin by Hünefeld in 1840 in Germany (McPherson A. 1991). In the 1930s, X-ray 
diffraction was applied to protein crystals (Bergfors TM. 2009). Since then, protein 
crystallization is mostly applied in X-ray crystallography for protein structure analysis. The 
growth of macromolecular crystals from solution may appear similar to conventional 
solution grown organic and inorganic crystals, however, there are many differences in 
physical and mechanical properties.  
1. Dimension. Organic and inorganic crystals can often be grown with dimensions of 
several centimeters. Protein crystals rarely exceed an edge length of one millimeter and 
are therefore much smaller.   
2. High solvent content. Mostly, protein crystals contain 40-60 % solvent by volume 
(Matthews BW. 1968.), which is contained in channels and gaps that pass among the 
molecules in the crystal lattice. In some extreme cases such as tropomyosin, solvent 
content can be as high as 90 %. (Caspar DL, et al. 1969.). Because of the high solvent 
content, the structure of protein crystals would be destroyed by any prolonged exposure 
to air due to dehydration. 
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3. Mechanical properties. Protein crystals are extremely fragile. For example, protein 
crystals crush if pressed with a metal edge, whereas conventional crystals crack when 
so challenged. This unique feature is often employed during the screening process in 
order to examine whether crystals are related to salt or protein.  
 
     Because of the aforesaid nature of macromolecular crystals and the conformational 
flexibility and microheterogeneity of proteins in solution, protein crystallization is not 
straightforward. The average crystallization success rate (i.e. preparation of X-ray quality 
crystals) is about 20 % for proteins that express in soluble form (Hui A and Edwards A. 
2003). By now, technical progress makes the task of crystallizing proteins much easier. 
However, protein crystallization is still a complex, multiparametric process 
(Klyushnichenko V. 2003). 
2.1.1 Physical aspects of protein crystallization 
Despite some different properties, proteins crystallize following the same process seen 
with lower molecular weight molecules. Crystallization is a phase transition phenomenon. 
The knowledge of protein solubility and the phase diagram is therefore essential to 
understanding and controlling the protein crystallization process. Figure 3 illustrates a 
generic phase diagram for protein crystallization, which can be obtained experimentally by 
varying two parameters, such as protein concentration and precipitant concentration, or 
protein concentration and temperature, at a time. The phase diagram is composed of four 
zones: in the undersaturated zone, the protein is dissolved and crystallization will never 
occur; in the metastable zone, protein solution is supersaturated, but no spontaneous 
nucleation will happen. However, crystal seeds are stable and will grow until system 
equilibrium has been reached; in the zone of moderate supersaturation (labile zone), 
protein forms crystals spontaneously; in the precipitation zone, where the protein is highly 
supersaturated, precipitate (amorphous form) is formed. The thick solid line in Figure 3 is 
the thermodynamic solubility curve of protein. Only soluble proteins and crystals are 
thermodynamically stable on this curve. For a defined solution, the maximum crystal yield 
will be (c0-ceq)/c0, where c0 is the initial protein concentration and ceq is the protein 
concentration on the solubility curve.   
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Figure 3. Schematic illustration of a typical protein crystallization phase diagram. The 
ordinate value is the concentration of protein; the abscissa value is the concentration of a 
crystallizing agent (precipitant). Other adjustable solubility parameters could be pH and 
temperature. The phase diagram can be divided into one undersaturated region and three 
supersaturated zones: precipitation, labile and metastabile zone. The thick solid line 
represents the solubility curve. The liquid and crystal phases of the protein are in 
equilibrium on the curve. 
 
     There are three phases during crystallization: nucleation, growth of crystal and 
cessation of growth (Feher G. 1986). Nucleation and growth of crystal occur in 
supersaturated solutions, in which the protein concentration exceeds its equilibrium 
solubility value. If no crystal seed is added, nucleation is a prerequisite for a successful 
crystallization process. As illustrated in Figure 4, protein molecules have a higher chance 
of encountering each other in the nonequilibrium state of supersaturation and produce 
dimers and higher oligomers. Solute protein molecules are continuously added to the 
aggregate, while others dissociate. However, very small aggregates are not stable due to 
the high surface tension, which results from a high surface-to-volume ratio (S/V ratio). If 
the dimension of the ordered aggregate reach a critical value, the S/V ratio has decreased 
enough to result in stable aggregates, association of the aggregate with new molecule will 
now be more rapid than dissociation and a crystal nucleus will be formed. The energy 
Publications & Manuscripts 12 
 
 
required to result in such critical nuclei is the critical activation free energy for nucleation. 
The system will remain in a nonequilibrium state for a long time, if the activation energy is 
high. The initial free energy level can be increased through higher supersaturation of the 
solution, resulting in reduced activation energy. Thus, supersaturation is the driving force 
for crystallization. Nucleation occurs typically at a supersaturation 2-10 fold higher than 
the equilibrium solubility (McPherson A. 1993). Crystal growth rate is also increased at 
higher supersaturation. However, disordered amorphous aggregates will be favored over 
crystals if the degree of supersaturation becomes too high.  
 
 
Figure 4. Formation of protein crystals from solution (McPherson A. 1999). As shown 
here,  a supersaturated solution (at the left) is at a higher energy state than crystalline state 
the system must surmount an energy barrier to get to reach the lowest energy equilibrium 
state (at the right).  
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     After nucleation, the nucleus will continue to grow through the addition of monomers 
or small aggregates from solution. Three dominant growth mechanisms were reported by 
observation of different protein crystals using atomic force microscopy (AFM) (Malkin AJ, 
et al. 1995.; Kuznetsov YG, et al. 1996): 1) two-dimensional nucleation on surfaces and 
lateral expansion; 2) spiral dislocations; 3) irregular and rough growth of crystal surface, 
known as normal growth. Crystals stop growing once the protein concentration reaches its 
thermodynamic solubility.  
2.1.2 Considerations and procedures for protein crystallization 
Protein solubility can be affected by different factors, including type and concentration of 
precipitant, pH value, ionic strength and solution temperature. The chemical composition 
(precipitant) of the solution is one of the extensively investigated factors during screening 
of crystallization conditions. As shown in Table 1 (McPherson A. 1999), different salts, 
polymers, organic solvents and nonvolatile alcohols are used in crystallizations. 
Table 1: Frequently used precipitants in macromolecular crystallization (McPherson A. 
1999) 
Salts Organic solvents Polymers 
ammonium sulfate Ethanol PEG 1000, 3350, 6000, 8000, 
Jeffamine T 
PEG monomethyl ester 
PEG monostearate 
Polyamine 
Lithium sulfate or chloride Propanol and isopropanol 
Sodium or ammonium citrate 1,3-Prapanediol 
sodium phosphate 2-methyl-2,4-pentanediol 
sodium or ammonium chloride Dioxane 
Sodium or ammonium acetate Acetone  
Magnesium or calcium sulfate Butanol  
Cetyltriethyl ammonium salts Acetonitrile  
Calcium chloride Dimethyl sulfoxide  
Ammonium or sodium nitrate 2,5-Hexanediol  
Sodium or magnesium formate Methanol  
Sodium or potassium tartrate 1,3-Butyrolactone  
Cadmium sulfate Ethylene glycol 400  
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      As salt concentration in solution is increased, solubility of most proteins is reduced 
because of the “salting out” effect. The reason for “salting out” is the competition of salt 
ions and protein molecules for water, since they all require hydration layers to maintain 
solubility (Baldwin RL. 1996). Less water molecules are available for proteins at high 
ionic concentrations. As a consequence, protein molecules self-associate through 
hydrophobic interaction. The ability of salting out is proportional to the square of the 
valences of the ionic species composing the salt (Cohn EJ and Ferry JD. 1943). Divalent 
ions, such as sulfates and phosphates, are the most efficient precipitants. In addition to 
salting out, there are also specific protein-ion interactions that may have important 
consequences (Hofmeister F. 1888; Ries-Kautt M and Ducruix A. 1989). It is therefore not 
sufficient to screen only one or two types of salt.  
     Polyethylene glycol (PEG), which is a polymer of ethylene oxide produced in various 
lengths, is another commonly used precipitating agent. In fact, PEG ranks first in the list of 
successfully used protein precipitants, and over 50 % of published protein crystals were 
obtained using PEG (Tanaka S and Ataka M. 2002; Roussel A, et al. 1990). PEG induces 
the attractive interaction between protein molecules by volume exclusion, as first explained 
in Asakura and Oosawa’s depletion model (Asakura S, Oosawa F. 1954; Asakura S, 
Oosawa F. 1958; Budayova M, et al. 1999). Because of the high molecular weight (MW) 
and the long structure of PEG, protein molecules in solution are excluded from the 
hydrodynamic volume of PEG, resulting in concentration of protein. Once the solubility is 
exceeded, protein precipitation occurs. This depletion force rises with increasing MW and 
concentration of the polymer in solution. Therefore, control of MW and polymer 
concentration is needed for protein crystallization. The most useful PEGs have been those 
in the range MW of 2000-8000 Da, and most protein crystallize within a narrow range of 
4-20% (w/v) PEG concentration (McPherson A, 1999). 
     Organic solvents, such as ethanol, acetone and acetonitrile, can be used to decrease 
protein solubility efficiently. Such organic solvents lower the dielectric constant of bulk 
solvent and increase the effective strength of electrostatic interaction, both repulsive as 
well as attractive (Arakawa T, et al. 2011). This leads to intermolecular polar interactions 
that allow self-association of protein molecules (Fennema OR. 1996): first, the increased 
repulsive intramolecular electrostatic interactions cause protein unfolding; next, interior 
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peptide groups of protein are exposed; at last, intermolecular attractions occur between 
oppositely charged groups, which results in a reduction of protein solubility. To minimize 
denaturation of the protein, organic solvents should normally be used at low temperatures  
(? 4°C) and ionic strength should be maintained as low as possible (McPherson A, 1999).  
The most generally used nonvolatile alcohols are methylpentanediol (MPD) and 
hexanediol.    
     In addition to precipitating agent, pH value and temperature of solvent are also factors 
to be investigated in searching crystallization conditions. Proteins carry negative or 
positive charge due to the acid and basic side chains of their amino acids. In the acidic pH 
range, lysine, arginine and histidine for instance protonate, thus protein molecules carry a 
positive charge, while in the basic pH range, protein is negatively charged due to 
deprotonation of aspartic and glutamic acid. In solution, protein molecules repel each other 
because of the like-charge on surface. This electrostatic repulsion will be minimized at 
isoelectric pH (pI), at which the charge of side chains compensate each other. The lack of 
net charge makes protein molecules more likely to aggregate and may cause protein 
precipitation. For many years it was assumed that the optimal pH value for protein 
crystallization should be its pI, since the solubility of protein is minimal at the pI value. 
However, some reports indicated that there is no correlation between pI value and the pH 
at which proteins were crystallized (Gilliland GL. 1988), probably because protein incline 
to form amorphous aggregate instead of crystal at its pI. Thus, screening a broad pH range 
is still necessary. In comparison to pH value, solution temperature may have little impact 
on crystallization. For most proteins, the dependence appears to be rather shallow 
(McPherson A, 1999). From a practical standpoint, temperature is almost always set near 
room temperature (22°C-25°C), and all trials are generally duplicated at 4 °C, i.e. in a cold 
room (Kundrot CE. 2004). The different solubility behavior may give information as to 
whether temperature is likely to play an important role (McPherson A, 1999). In addition, 
studies of protein crystallization using AFM (Malkin AJ, et al. 1996a, 1996b, 1996c), have 
indicated that temperature may have a major effect on the growth mechanisms of the 
crystals (see Chapter 2.1.1). Thus, temperature can have a major influence on the crystal 
quality.  
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     As mentioned above, many factors affect protein solubility, and protein crystallization 
still remains a trial-and-error process. To find preliminary crystallization conditions, 
factorial designs such as sparse matrix and grid screens are used to screen a wider range of 
conditions (pH, buffer, precipitant, additive, etc) with a modest number of experiments. 
Sparse matrix screens are employed to evaluate a large number of parameters with a 
limited amount of protein sample. Prefabricated sparse matrix screening kits are mostly 
composed of reagent cocktails that are biased toward previous successes (Jancarik J and 
Kim SH. 1991), which might increase the success rate of initial crystallization screenings. 
However, because protein and precipitant concentrations are not extensively sampled, it is 
then difficult to make a statistical conclusion of protein solubility using this screening 
procedure if no crystal is formed in crystallization trails. Grid screen is another approach, 
in which several precipitant types are screened more systematically, varying pH-value and 
concentration (Bergfors TM. 2009). Through experimental design, crystallization trials can 
be easily and rapidly designed and interpreted in a grid screen experiment. However, DoE 
requires more experiments to cover a relatively narrow parameter range. Therefore, this 
method is mostly employed for the optimization of crystallization conditions after initial 
screen. In this work, different commercial sparse matrix screening kits were used for initial 
setups. Grid screen was employed for fine-tuning or optimization once initial 
crystallization conditions had been found. 
     When searching for crystallization conditions, an undersaturated protein solution is 
produced initially. Then, solvent properties are altered such as to slowly reach the 
supersaturation region. This is important to avoid a sudden rise of free energy of the 
system, which would result in the formation of amorphous aggregates. There are a number 
of devices, procedures, and methods for attaining a supersaturated protein solution by 
changing chemical and/or physical properties of the system in a gentle and continuous 
manner. The most common methods are presented in Table 2 (McPherson A, 1999). 
Among them, the most used methods in this work were batch crystallization and vapor 
diffusion. 
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Table 2. Crystallization methods (McPherson A, 1999). 
1. Bulk crystallization 
2. Batch method in vials 
3. Evaporation 
4. Bulk dialysis 
5. Concentration dialysis 
6. Microdialysis 
7. Liquid bridge 
8. Free interface diffusion 
9. Vapor diffusion (sitting drops) 
10. Vapor diffusion (hanging drops) 
11. Sequential extraction 
12. pH-induced crystallization 
13. Temperature-induced crystallization 
14. Crystallization by effector addition 
  
     Vapor diffusion is the most widely used crystallization technique, due to its 
convenience and the diversity of variables that can be controlled. Virtually all vapor 
diffusion trials are carried out at microliter scale with volumes of mother liquor solution 
from 2 to 20 µl (Weber PC. 1997). Two common procedures, sitting drop and hanging 
drop, are involved in this approach, depending on the position of the experiment drop. 
Figure 5 illustrates the hanging drop approach as an example. At the beginning of the trial 
a crystallization drop containing protein sample and precipitant is dispensed onto a surface 
in an airtight chamber with a reservoir solution containing the same precipitant but a higher 
concentration than it is found in the droplet. Thus, vapor pressure of water over the 
reservoir solution is lower than that over the crystallization drop. Water will be transported 
from droplet to reservoir until equilibrium between the two is achieved. Meanwhile, 
nonvolatile chemicals (PEG, salts, protein) will remain in the drop. Since the volume of 
reservoir is much larger than that of the drop, the ultimate precipitant concentration in the 
droplet will correspond to the initial concentration of precipitant in the reservoir. The 
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increased concentration of chemical components in the drop will drive the protein into 
supersaturation.  
 
Figure 5. Schematic representation of the hanging drop method. A protein containing drop 
is sealed in a closed system with a reservoir that is much larger in volume. Since the initial 
concentration of precipitant in drop ([Cp]drop) is lower than that in reservoir ([Cp]reservoir), 
water will be transported from droplet to reservoir until equilibrium is achieved. The 
concentrations of all nonvolatile chemicals inclusive protein rise thus due to the decrease 
of volume.  
 
     Batch crystallization is the simplest and oldest technique used for the protein 
crystallization (McPherson A, 1999). This technique is attractive, because it is simple to set 
up and reproducible. Two or more solutions are mixed together for each experiment, and 
unlike in vapor diffusion, the protein concentration will not change unless protein 
molecules are transferred from solution into amorphous aggregates or crystals. For batch 
processes at laboratory scale (several microliters), a paraffin oil layer is used to prevent 
dehydration. Because of its simplicity, the technique is amenable to interface with different 
observational systems designed to monitor and record the process of protein crystal 
growth. Examples are light scattering studies of nucleation (Malkin AJ, et al. 1993; George 
A and Wilson WW. 1994; Veesler S, et al. 1994), time lapse photography (Koszelak S, et 
al. 1991), or AFM (Land TA, et al. 1995; Kuznetsov YZ, et al. 1997). Moreover, a batch 
process is the method of choice for many industrial-scale production crystallizations 
(Bergfors TM. 2009), because it can be easy up- or downscaled. 
Reservoir
[Cp]drop< [Cp]reservoir 
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2.1.3 Bulk crystallization for purification 
Protein crystallization is mostly applied for structure analysis. For this application, protein 
purity is an important factor for growth of highly ordered crystals. However, proteins 
indeed can crystallize from impure solutions, since the specific protein-protein interactions 
associated with the growth of crystals appear to preclude the inclusion of contaminating 
species (Przybycien TM. 1998). Although crystallization was used early as a protein 
purification method (Jakoby WB. 1971), this application has been ignored for a long time, 
perhaps due to the difficulty in seeking conditions to obtain protein crystals with high 
quality. The experience from crystallography indicates that the presence of impurities 
makes crystallization very difficult (Giege R, et al. 1986.; Lorber B, et al. 1993; 
McPherson A. 1985). However, biochemical engineers have different requirements on 
crystals than crystallographer. Defect densities and diffraction resolution of crystals, which 
are important for structure determination, are irrelevant for bulk crystallization. Thus, 
crystals unsuitable for structural characterization may be suitable as a final product form 
(Przybycien TM, 1998). In addition, because of advances in fermentation technology over 
recent years, recombinant techniques allow the creation of strains where few other proteins 
are secreted and fewer impurities are therefore found in the product stream (Jacobsen C, et 
al. 1997). Such progresses make protein crystallization more amenable to purification at 
process scale. Besides the quality of crystals, requirements regarding precipitant, growth 
rate and crystallization yield are also different between structure analysis and purification 
applications. Some differences are summarized in Table 3.  
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Table 3. Success criteria for crystallography vs. bioseparation processes (Peters J, et al. 
2005) 
Criterion Crystals for crystallography Crystals for processes 
Precipitants Free choice Nontoxic, nonhazardous 
Precipitant costs No issue Important 
Process compatibility Not important Essential 
Crystal size Large is best (150-500 µm) small okay (10-20 µm) 
Packing quality (unit cells) High resolution Not important 
Crystallization yield Not important Very importang 
Growth kinetics Often slow (days to months) Fast (hours to days) 
Redissolution Not necessary Necessary 
Scalability of conditions Not important Very important 
Protein available for screening Critical restriction No restriction 
 
     To date, proteins purified by crystallization are mainly found among industrially 
produced enzymes. Lipase crystals and subtilisin crystals, for example, both have been 
produced from a fermentation broth that was only clarified by centrifugation and 
concentrated by ultrafiltration and diafiltration prior to the crystallization process (Shukla 
AA, et al. 2007; Jacobsen C, et al. 1998; Becker T and Lawlis VB. 1991). There are only a 
few such examples in biopharmaceutical processes one of which is the production of 
insulin using crystallization (Brange J. 1987.). However, the crystallization process is 
carried out late in the purification sequence where most of the impurities have already been 
removed (Jacobsen C, et al. 1997.). Because of the challenge from the increased protein 
titer to downstream processing, as a cheap and easily scaled-up separation and purification 
process, bulk crystallization has recently drawn more attention again for the recovery of 
pharmaceutical proteins.  
     Due to the possible influence of impurities present in fermentation broths, it is practical 
to place a crystallization step late in downstream processing. Implementation of 
crystallization as an intermediate or polishing step into the large-scale production of 
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aprotinin, a protease inhibitor used to decrease blood loss during surgery, has been 
described by Peters et al. (Peters J, et al. 2005.). Their work showed that crystal yield 
increased if crystallization was performed as a final step as opposed to an intermediate 
step. They also concluded that there were several advantages for proteins formulated in 
crystalline form: (1) high proteins concentration; (2) crystalline protein is stable and can be 
stored for years without significant product degradation. It was also reported that 
crystalline suspensions provide an improved method of delivery for therapeutic proteins, 
because of their low viscosity at high concentration (Yang MX, et al. 2003).  
     Placement further downstream provides a more pure and controlled feed solution to the 
crystallization process. However, placement earlier in the process would provide more 
advantages, because crystallization both concentrates and purifies the feed solution (Shukla 
AA, et al. 2007.), and moreover, this operation unit is cheaper than many chromatographic 
processes (e.g. protein A chromatography), which are commonly used in routine 
purification. Judeg et al. (Judge RA, et al. 1995) successfully crystallized ovalbumin from 
a solution containing lysozyme and conalbumin, which were added to the solution 
intentionally as impurities. The results indicate that conalbumin and lysozyme molecules 
were excluded from crystalline ovalbumin. The purity of ovalbumin was increased from 
86% (w/w) to 99% of total protein by one crystallization step. Although components in 
fermentation broths are mostly more complex, this study still demonstrates that protein 
crystallization may be carried out closer to cell culture and fermentation, with the benefit 
of very high enrichment.  
2.2 Characterization of protein protein interactions through virial coefficients 
2.2.1 Osmotic virial coefficients 
The osmotic virial coefficients appear as coefficients in the osmotic virial equation (Moon 
YU. 2011): 
  
 
???? ? ?? ? ??? ? ???? ??                                          (1)      
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where ? is the osmotic pressure, A2 and A3 are the second and third virial coefficients, c is 
the solute concentration, M is the molar mass, R is the gas constant, and T is the absolute 
temperature. The second virial coefficient A2 can be determined through the Zimm 
equation (Chapter 2.2.3), and reflects the magnitude and sign of two body interactions in 
dilute solution (Neal BL, et al. 1998). If the determined A2 has a positive values of 
magnitude ? 10-4 mol?mL/g2, repulsive interaction is dominant between molecules, which 
implies that solute molecules in solution prefer to interact with the solvent over interacting 
with themselves. A slight negative value on the other hand indicates attractive interactions. 
Solute molecules then tend to aggregate and precipitate from solution. Very large negative 
A2 values do not occur, because such thermodynamically poor solvents would not dissolve 
polymers at all (Podzimek S. 2011). George and Wilson (George A and Wilson WW, 
1994) correlated the second virial coefficient with increased an probability of protein 
crystallization and stated that crystallization only occurs when A2 is within a narrow range 
of slightly negative values between about -1.0 to -8.0×10-4mol?ml?g-2, the so-called 
“crystallization slot”. If A2 is strongly negative, formation of amorphous aggregation is 
more favorable because of the strong attraction between protein molecules. A2 therefore 
becomes a suitable parameter to predict protein crystallization, although cases of proteins 
crystallizing outside this slot have also been found (Bonnete F, Vivares D. 2002; Ebel C, et 
al. 1999; Hitscherich C, et al. 2000).  
2.2.2 Static light scattering 
Elastic or Raleigh light scattering is a phenomenon that occurs when molecules or particles 
with a diameter more than 1 nm present in solution (Ahrer K, et al. 2003). There are two 
main techniques for measurement of scattered light.  Static light scattering (SLS) measures 
the average intensity of scattered light at a given scattering angle and is applied for the 
determination of absolute molecular mass, molecule size and virial coefficients. Dynamic 
light scatting (DLS) or quasi-elastic light scattering measures the fluctuation of the 
scattered light intensity over time, due to the Brownian motion of the scattering particles 
(Ahrer K et al. 2003). In this work, only SLS is discussed and used.  
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     In a dilute polymer solution, the intensity of scattered light depends on (1) the intensity 
scattered by the solvent, and (2) the intensity scattered by the solute, i.e. the 
macromolecules. The difference between the two scattered intensities is defined as excess 
scattering, which provides information about the dissolved macromolecules (Podzimek S. 
2011). Excess scattering intensity depends on the molar mass M, the solute concentration 
c, and the interaction between macromolecules in solutions.  
     The basic equation that relates the intensity of scattered light with the properties of the 
macromolecules in solution is the Zimm equation (Zimm BH. 1948). 
 
      
     In the above equation, K* is an optical constant equal to [4?2n02(dn/dc)2]/(?4NA), n0 is 
the refractive index of solvent at the incident wavelength ?, dn/dc is the specific refractive 
index increment of scattering macromolecules, NA is Avogadro’s number, R(?) is the 
excess Rayleigh ratio at the angle ? (the angle between the scattering direction and the 
incident light), P(?) is the particle scattering factor, A2 is the second virial coefficient. 
Macromolecules do not have a single molar mass, therefore molar mass M here is the 
weight-average molar mass Mw, which is defined as follows: 
 
 
where ni is the number of mass point with molar mass Mi. 
     The specific refractive index increment dn/dc, appearing in the optical constant K*, 
characterizes how the refractive index of a solution changes with the concentration of the 
solute (Huglin MB. 1972). Thus, dn/dc can be defined as the slope of the dependence of 
the refractive index of a polymer solution on its concentration. For the majority of soluble 
proteins dn/dc has approximately the same value, i.e. 0.185-0.187 mL/g (Ball V, Ramsden 
JJ. 1998; Wen J, et al. 2000) and is constant over a wide range of the protein concentration.  
???????? ? ???????? ??? ? ? ? ?                                                  (2) 
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     The excess Rayleigh ratio R(?), named after the physicist Lord Rayleigh, who 
discovered light scattering phenomenon, describes the angular dependence of scattered 
light and is defined as: 
 
 
where I? is the scattered light intensity of the solution, I?, solvent is the scattered light 
intensity of the solvent, I0 is the intensity of the incident light, V is the scattering volume of 
sample, r is the distance between the scattering volume and the detector. In practice, the 
light scattering intensity is measured as voltage yield by photodiodes:  
 
 
here, V?, V?, solvent and Vlaser are detector signal voltages of the solution, solvent and laser, 
respectively, f is an instrumental constant related to the geometry of the scattering cell, the 
refractive indices of the solvent and the scattering cell. This calibration constant is 
determined by a solvent of well-known Rayleigh ratio, e.g. toluene.  
     The scattered light from different mass points of a large particle can interfere with each 
other. Therefore, the intensity of the resulting radiation is smaller than the sum of 
particular intensity of light scattered by all the individual mass points. This phenomenon is 
called intramolecular interference of scattered light, which is described by the particle 
scattering factor P(?) in equation (2). P(?) is defined as the ratio of the intensity of light 
scattered at an angle of observation to the intensity of light scattered at zero angle (where 
incident light enters) (Podzimek S. 2011) and is decreased with increasing angle, if the 
diameter of the particle is larger than ?/20 (anisotropic scattering). Thus, the study of P(?) 
leads to knowledge concerning the shape of the macromolecules and more specifically to a 
measurement to the mean square radius of gyration (Albrecht AC. 1957; Zimm BH. 1948).   
     In addition to intramolecular interference, light scattered by different macromolecules 
also interferes. The intermolecular interference effect is characterized by the second and 
higher virial coefficient (A2, A3…) and provides information on thermodynamic properties 
???? ? ?????????????????????                                                              (4)  
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of the protein-solvent system. Although Equation (2) contains further terms with the third 
and higher virial coefficients, they can be neglected if light scattering is measured at low 
concentrations (Podzimek S. 2011). A2 represent non-ideality in dilute solution, and 
characterizes the result of macromolecular interactions between particles in solution 
(Bonnete F, Vivares D. 2002), contributed by electrostatics, van der Waals interactions, 
excluded volumes, hydration forces, and hydrophobic effects (Curitis RA, et al. 2001; Haas 
C and Drenth J. 1999).  
2.2.3 Determination of virial coefficient by static light scattering 
To obtain the second virial coefficient A2, a Zimm plot (Figure 6), that is, a plot of 
K*c/R(?) versus [sin2(?/2)+kc] is constructed according to Equation (2). The constant k is 
set to spread out the experimental data points and affects thus only the visual appearance of 
the plot, but has no influence on the obtained results (Podzimek S. 2011).   
 
Figure 6. Typical Zimm plot, showing light scattering intensity R(?) as a function of 
concentration c and scattering angle ? (Podzimek S. 2011).  
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     The Zimm plot processes the three-dimensional function R(?) versus c and ? using a 
two-dimensional plot and allows simultaneous extrapolation of the concentration and 
angular dependence of the light scattering intensities to zero angle and zero concentration. 
The molecular mass, virial coefficients are obtained through a global fit of angular 
dependence of the light scattering data at different solute concentration and a subsequent 
extrapolation of the data at zero concentration and zero angle. The slope of the 
concentration dependence at zero angle yields then the second virial coefficient according 
to the following equation: 
  
      
     Multi-protein systems require not only information for self interaction between protein 
molecules of the same species, but also for cross interaction between protein molecules of 
the different species. In analogy to the aforementioned second self virial coefficient A2 
(SVC), which was used to represent interactions in one protein system, second cross virial 
coefficient A11 (CVC) are employed to characterize the magnitude and direction (repulsive 
or attractive) of cross interactions in multi-protein system. A11 may help to determine 
optimum conditions to precipitate or crystallize a target protein from an aqueous protein 
mixture (Choi HS, Bae YC. 2009.) and can also be obtained through light scattering 
measurement in batch mode.  
2.3 Impact of osmolytes on protein stability 
Protein stability can play an important role in determining crystallization behavior. Protein 
aggregation can occur through a number of distinct mechanisms (Philo JS, Arakawa T. 
2009): 1. reversible association of the native monomer due to complementary areas on the 
protein surface; 2. aggregation caused by chemical degradation or modification, which 
may create new sticky patches on the surface or change the electric charge and reduce 
electrostatic repulsion between monomers; 3. conformation change due to binding of the 
native monomer to a surface, which leads to partial unfolding and protein self-association; 
4. association of unfolded proteins promoted by environmental stress. Among them, 
????????????? ? ??? ? ? ? ??                                                         (6) 
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mechanism 4 represents the most common form of all possible deteriorations (Wang W. 
2005) and is mainly considered in this work. Partially or fully unfolded proteins reduce the 
probability of crystallization. (Price WN, et al. 2009). In addition, aggregation of 
pharmaceutical proteins, which could occur during downstream process, also results in 
activity loss and immunogenic adverse reactions. Therefore, protein aggregation must be 
avoided in general when working with biopharmaceuticals and specifically during a 
crystallization process step. 
     Several environmental factors may induce protein aggregation through unfolding, 
including temperature, ionic strength, pH, salt type and concentration and mechanical 
stress. Issues of protein stability arise when cells are subjected to such environmental 
changes that under ordinary circumstances may cause proteins to precipitate (Bolen DW. 
2004). Numerous eukaryotic organisms have successfully adapted to such stresses through 
making and accumulating significant concentrations of small organic molecules 
(Hochachka PW, Somero GN. 2002). These so-called osmolytes have the ability to 
stabilize proteins against denaturation stresses in order to maintain cell viability. Most of 
them belong to three substance classes (Yancey PH, et al. 1982): (1) polyhydric alcohols 
and sugars (polyols), such as glycerol, sorbitol, sucrose; (2) amino acids and their 
derivatives such as proline, glycine, glutamine, alanine; and (3) methylamine compounds 
such as trimethylamine-N-oxide (TMAO). The basic mechanism for their stabilizing 
property has been shown to correlate with the preferential exclusion of osmolytes from the 
vicinity of the protein (Bolen DW. 2001). Exclusion of stabilizing osmolytes decreases the  
entropy of the osmolyte / protein system in the unfolded state, because less volume is 
accessible to the osmolytes if the unfolded protein occupies a larger volume. Thus 
compaction of the (folded) protein is energetically more favorable when these osmolytes 
are present.  
     Protein stability comes in two flavors: (i) thermodynamic stability, which is equal to ?Gunf, the free energy of unfolding; (ii) kinetic stability, which is related to a high free-
energy barrier “separating” the native state from the unfolded or aggregated forms, when 
the latter are at a lower free energy level. (Sanchez-Ruiz JM. 2010). The effect of 
osmolytes on thermodynamic stability has been studied extensively (Yancey PH et al. 
1982; Taneja S, Ahmad F. 1994; Santoro MM, et al. 1992). However, thermodynamic 
stability may not be the critical factor for many protein applications of (Rodriguez-Larrea 
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D, et al. 2006) and does not necessarily correlate with “stabilization” in the sense of 
preserving functionality over extended periods. In many cases, the kinetic stability of 
proteins is thus relevant, because it relates more directly with practical parameters of 
interest, such as shelf-life or half-life time for degradation (Pey AL, et al. 2008). Kinetic 
stability has also been addressed in osmolyte studies, for instance, osmolytes were able to 
slow down insulin fibrillation (Nayak A, et al. 2009) or to increase the storage half-life of 
human recombinant growth factor (Chen BL, Arakawa T. 1996). 
     It is important to note that osmolytes do not always exhibit protein-stabilizing 
properties. On the one hand, protecting osmolytes can sometimes be protein-specific: 
osmolyte that stabilize one protein may have a destabilizing effect on other proteins. For 
example, glycine betaine has been reported to stabilize RNAse A, but destabilizes ?-
lactalbumin at low pH (Singh LR, et al. 2009). On the other hand, osmolytes can also be 
stress-specific. It was reported that TMAO is a potent stabilizer at neutral pH but 
destabilizes proteins at low pH (Singh R, et al. 2005).  
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Abstract 
Crystallization conditions of an intact monoclonal IgG4 (immunoglobulin G, subclass 4) 
antibody were established in vapor diffusion mode by sparse matrix screening and 
subsequent optimization. The procedure was transferred to microbatch conditions and a 
phase diagram was built showing surprisingly low solubility of the antibody at 
equilibrium. With up-scaling to process scale in mind, purification efficiency of the 
crystallization step was investigated. Added model protein contaminants were excluded 
from the crystals to more than 95 %. No measurable loss of Fc-binding activity was 
observed in the crystallized and redissolved antibody. Conditions could be adapted to 
crystallize the antibody directly from concentrated and diafiltrated cell culture supernatant, 
showing purification efficiency similar to that of Protein A chromatography. We conclude 
that crystallization has the potential to be included in downstream processing as a low-cost 
purification or formulation step. 
Key words: protein crystallization, antibody, purification, protein A chromatography 
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Introduction 
Therapeutic monoclonal antibodies (mAbs) were introduced into the market in 1986. Since 
then, processing technologies for this class of therapeutics have seen enormous progress as 
exemplified by recombinant cell lines producing titers in the range of 10 grams per liter of 
cell culture. Downstream processing technology currently relies heavily on protein A 
chromatography, a fast and highly selective capturing step, followed by additional 
chromatographic procedures such as ion exchange or hydrophobic interaction 
chromatography. Although the purity of mAb achieved after Protein A chromatography 
usually exceeds 90 %, further purification steps are required to meet the exceptionally high 
purity targets of biopharmaceuticals. The major drawback of chromatographic procedures 
is the high cost of adsorption media, which can amount to more than ten thousand US 
dollar per liter of Protein A resin. Therefore, more economic procedures able to replace at 
least one chromatographic operation are subject to extensive research.  
     Protein crystallization, which has been mostly applied in protein structure analysis, has 
been recognized in principle as a method of protein purification [1, 2]. Within a crystal, 
protein molecules form a regular lattice able to exclude other proteins as well as misfolded 
protein molecules of the same type. Therefore, as routinely applied to small molecules, 
crystallization can also be used as a cheap and scalable purification procedure [3]. Earlier 
work has demonstrated the feasibility of protein purification by crystallization e.g. for an 
industrial lipase [4] or the model protein ovalbumin [5]. However, the only 
biopharmaceutical routinely crystallized at industrial scale and with excellent recovery 
yields is insulin [6]. Insulin is a small and extraordinarily stable peptide able to refold 
easily into its native structure even after exposure to organic solvents. It is crystallized late 
in the purification sequence where most of the impurities have already been removed [4]. 
     Additional benefits of protein crystallization from a formulation perspective are the 
higher stability of crystalline proteins in comparison to protein solutions, making 
crystalline formulations an attractive alternative with potentially longer shelf life, and the 
possibility to control delivery of a protein by making use of crystal dissolution kinetics [7]. 
The latter has been investigated extensively in the context of insulin formulations [8].  
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     For immunoglobulin, the use of this technique as a means of purification or formulation 
is not yet a routine procedure. Several authors studied phase behavior of mAbs with the 
goal to identify a rational approach leading to crystallization conditions [9-11]. The work 
has been complicated by the fact that in addition to crystallization other phenomena such 
as precipitation, phase separation and the formation of gel-like phases can occur that 
kinetically trap the system far from equilibrium and as a consequence reduce the yield of 
crystalline protein or inhibit crystal formation completely. 
     In our study, we chose an IgG4 mAb that readily crystallizes under a range of 
conditions, allowing us to optimize the procedure with respect to mass and activity 
recovery and degree of purity. Focusing on a simple system composed of solvent and 
crystals, we were able to identify the solubility limit in a phase diagram and use this as the 
starting point for up-scaling to a process step conforming to GMP requirements. The aim 
of this work is to show how initial crystallization conditions can be improved and 
optimized to result in a process step that delivers high purity and high recovery. We want 
to point out however, that for any individual antibody, those initial conditions have to be 
identified by screening. There is yet no method available that allows predicting 
crystallization conditions from protein sequence or general physico-chemical parameters. 
Nor can crystallization conditions be transferred from one protein to another even if they 
are very closely related in sequence. [12] The osmotic virial coefficient B22, which has 
been shown to often adopt values within a certain range ("crystallization slot") under 
conditions promoting protein crystallization [13], has not proven to become a general 
predictor for proteins difficult to crystallize [10] [14].  
 
Materials and Methods 
Antibody 
Clarified cell culture supernatant of a CHO derived cell line secreting monoclonal IgG4 
type antibody mAb04c as well as Protein A-purified mAb04c were kindly provided by 
Boehringer Ingelheim Pharma GmbH (Biberach, Germany).  
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Crystallization technique 
Wizard™ I, II, III Crystal Screen kits were from Emerald BioSystems (Bainbridge Island, 
US). Basic and Extension Kits were from Sigma (Taufkirchen, Germany).  
     For protein crystallization, both vapor diffusion and microbatch techniques were 
utilized. The methods were performed according to Bergfors [15]. 96 well crystallization 
plates from Corning (Amsterdam, The Netherlands) and Crystalbridge™ (45 µl) from 
Greiner bio-one (Germany) were used for sitting drops. 24 wells plate (Greiner bio-one) 
were used for hanging drop and 60 wells plate (Greiner bio-one) for microbatch 
crystallization. The protein solution was filtered through 0.2 µm filter (Sartorius, 
Germany) before crystallization. 
Concentration and buffer exchange 
Protein A-purified mAb was dialyzed overnight against 20 mM Tris buffer pH 7.0 at 4 °C, 
and was then concentrated to the desired concentration with Vivaspin™ 500 centrifugal 
filter (30 kDa MWCO, Sartorius) by centrifugation (15000g, 4°C). Cell culture supernatant 
was diafiltrated using 7 volumes of 20 mM Tris, 50 mM Histidine, pH 7, and 30 kDa 
MWCO membrane cassettes (Hydrostat, Sartorius, Germany). Next, mAb was 
concentrated with Vivaspin™ 500 to the required concentration.  
     Concentration of purified mAb was determined photometrically at 280 nm using a 
NanoDrop® 1000 (Thermo Scientific, US) photometer, whereas mAb concentration of 
culture supernatant was measured by size exclusion HPLC (SE-HPLC) on a Tosoh TSK-
GEL 3000 SWXL column at 25 °C. HPLC system was HP1100 from Agilent (Waldbronn, 
Germany). Elution buffer was 0.05 M Tris/0.15 M NaCl, pH 7, the flow rate was 1 ml/min. 
Chromeleon
®
 software (Dionex, Sunnyvale, US) was applied for chromatogram recording. 
Protein was detected at 225 nm and integrated elution peaks were compared to a mAb 
standard calibration curve. 
     Purity of mAb was estimated by SE-HPLC and by SDS-PAGE on 12.5 % Laemmli 
gels. SDS gels were stained with Coomassie Blue or silver.   
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Distinction of crystals and amorphous precipitate 
Crystals and amorphous precipitate were distinguished through birefringence using a 
microscope (Nikon Eclipse 80i, Düsseldorf, Germany) equipped with polarizing filters. 
Birefringent protein crystals change color upon rotation of the polarizing filter, while 
amorphous precipitate does not show this behavior.  
 
Harvest of protein crystal 
Crystals were separated from the mother liquor by 10 min centrifugation at 4 °C and 
10,000g and washed 3 times with reservoir solution, each volume of the wash reservoir 
being the same as that of the original sample of crystal suspension. The crystals were 
redissolved in 100 mM sodium acetate pH 4.0, and stored at 4 °C for further analysis. 
Determination of phase diagram 
The apparent phase diagram was obtained from microbatch experiments in 60 well plates 
at room temperature (about 22 °C). 1.5 µL of protein solution were mixed with an 
equivalent volume of crystallization reagent and covered by paraffin oil (Hampton 
Research, Aliso Viejo, US). Experiments were monitored visually under microscope over a 
period of five days. No visual changes were detected starting from day three.  
     In the metastable zone spontaneous nucleation does not occur, and therefore 
equilibrium cannot be reached through the growth of crystals starting from a supersaturated 
solution. The solubility limit of mAb04c was therefore measured by dissolving crystals in a 
protein-free solution until equilibrium reached. MAb04 was first crystallized as controlled 
by microscopy at 8 mg/ml protein, 8 % w/v PEG 8000, 0.2 M Ca(OAc)2, 0.1 M Imidazol, 
pH 7 using microbatch process. Crystals were harvested, homogenized with Seed Bead™ 
(Hampton Research), and resuspended in deionized water. 20 µl Aliquots of this 
suspension were added to 1.5 ml centrifuge tubes.  Subsequently, 100 µl of precipitant 
solution as above, but with varying PEG 8000 concentrations was added to each aliquot. 
The amount of crystallized protein was in excess so that crystals would not dissolve 
completely. After five days mixing in a Thermomixer Campact (RT, 300 RPM, Eppendorf, 
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Germany), the protein concentration in the supernatant was determined via A280 
measurement in a NanoDrop photometer following 10 min centrifugation at 10,000 g. 
Control experiments showed that equilibrium had been attained at this time. 
Binding activity measurement 
     The functional integrity of the Fc portion of crystallized mAb was confirmed by binding 
to immobilized Protein A on a Biacore
®
 T100 SPR instrument (GE Healthcare, Germany) 
as described by the manufacturer.   
Spiking experiments with protein contaminations, DNA and bacteriophage  
     Host cell proteins (HCPs), virus and DNA are critical impurities in the production of 
biopharmaceuticals. Therefore, spiking experiments using model protein impurities, 
genomic DNA and bacteriophage T7 as a virus model were carried out. 
     For HCP spiking, purified mAb (8.6 mg/ml) was mixed with lysozyme (14.3 kDa, 10 
mg/ml, Fluka, Schwitzerland) or BSA (bovine serum albumin, 66 kDa, 10 mg/ml, Carl 
Roth, Germany) and then crystallized by sitting drop vapor diffusion. Precipitant solution 
was 10 % w/v PEG 8000, 0.2 M Ca(OAc)2, 0.1 M Imidazol, pH 7 as above.  
      For DNA and phage spiking, DNA at a concentration of 25 µg DNA/mg mAb or phage 
at a concentration of 6.4×10
7
 PFU (Plaque Forming Unit)/mg mAb were added to mAb04c. 
Crystallization was carried out as above. 
     Bacteriophage T7 and E. coli strain B were kindly provided by A. Kuhn (Hohenheim 
University, Germany). Bacteriophage concentration was determined by plaque counting 
following the online protocol [16]. E. coli was cultured in LB-Medium pH 7.5. Phage was 
diluted in 0.85 % phosphate buffered saline (PBS buffer: 8 g/l NaCl, 0.2 g/l KCl, 1.44 g/l 
Na2HPO4, 0.24 KH2PO4, pH 7.4). Agar plates contained 20 g pepton, 3.5 g NaCl, 15 g 
agar, 1.5 % w/v glucose, 6.75 mM Na2HPO4, 8 ml 1 % w/v aniline blue (filtered through 
0.2 µm sterile filter) per liter. Soft top agar was 7 g agar per liter. All solutions were 
autoclaved.  
     DNA concentration was measured using a 96 wells microplate (Greiner bio-one) 
SYBR
®
 Green I (Invitrogen, Germany) assay [17]. Chromosomal DNA was from salmon 
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sperm (Fluka, Germany). SpectraMax
® 
microplate reader was from Molecular Devices 
(US). Excitation: 488 nm /Emission: 520 nm.  
 
Results and Discussion 
Seven hits (microcrystals or crystals) were found in sparse matrix screening using 
commercial screen kits. After 3 repetition tests with the 7 conditions found, the most robust 
condition (10 % w/v PEG 8000, 0.2 M Ca(OAc)2, 0.1 M Imidazol, pH 7) was chosen as the 
starting point of a phase diagram. Crystals obtained were coffin-shaped structures (Figure 
7). Mechanical rigidity, as qualitatively assessed by micromanipulation using "Crystal 
tools" (Hampton Research) under microscope, was high compared to "needles" found in 
other screening experiments. When the seeding stock was prepared (see above) omission 
of the "Seed bead", acting as a ball mill, even vigourous vortexing resulted in a preparation 
that contained relatively large crystals and fragments. We therefore expect that those 
crystals will not fragment extensively under mechanical stress, e.g. in a stirred crystallizer, 
and will be suitable for subsequent solid-liquid separation. Protein solubility was studied as 
a function of the concentrations of protein and PEG 8000 in 0.1 M Imidazol 0.2 M calcium 
acetate pH 7 at RT (Figure 8). The solubility of mAb decreased with increasing precipitate 
concentration. Crystals were observed at PEG 8000 concentrations exceeding 5 % (w/v). In 
the protein concentration range between 10 and 14 mg/ml, there was a broad crystallization 
region between 5 and 9 % PEG 8000.  
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Figure 7. Micrograph of crystals of mAb04c under polarized light. 3 µl microbatch. 
Conditions: 1.5 µl 20 mg/ml mAb04c in 20 mM Tris, 50 mM Histidine, pH 7 plus 1.5 µl 
12 % (w/v) PEG 8000, 0.4 M calcium acetate in 0.2 M Imidazol, pH 7, RT. The broken 
crystal (intentionally) indicates that the dimension of crystal is about 100~150 µm × 10~20 
µm× 10~20 µm. 
 
 
Figure 8. Phase diagram of mAb04c with PEG 8000 as precipitant. Buffer: 0.1 M imidazol, 
0.2 M calcium acetate, pH 7.0, RT.    
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     However, this method does not provide the solubility limit, as crystallization does not 
occur spontaneously in the metastable region where kinetic effects prevent nucleation [12].
 
Therefore, the solubility limit was determined by preparing saturated solutions in 
equilibrium with crystalline protein and measuring the protein concentration in the 
supernatant. The solubility limit (solid line in Figure 8) was found to be located far away 
from the crystallization zone at protein and precipitant concentrations at least one order of 
magnitude below the limit of spontaneous crystallization. This result indicates that 
mAb04c crystallizes spontaneously only at high supersaturation. 
     The crystallization of mAb04c in the presence of contaminating protein was examined 
by spiking with model protein impurities as described by Judge et al [5]. Crystals appeared 
after 2 days and the crystal shape was indistinguishable from crystals of non-contaminated 
mAb04c. Crystals were harvested after 5 days and then redissolved in 100 mM Sodium 
Acetate pH 4. On SDS-PAGE, neither Lysozyme nor BSA still present in the mother liquor 
was detected in the redissolved mAb crystals (Figure 9, lanes 3 and 6). The only bands 
detectable resulted from the original mAb protein (IgG light and heavy chains), plus a band 
probably resulting from partially degraded heavy chain. The contaminants Lysozyme and 
BSA were only present in the mother liquor (lanes 2 and 5) and in the wash solutions 
(lanes 4 and 7). Silver staining is reported to detect individual bands exceeding 10 
nanograms, indicating that more than 90% of the protein contaminations had been 
removed. 
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Figure 9. SDS-PAGE of HCP spiking experiment. Silver-staining. Lanes: (1) mAb04c, 
standard; (2) mother liquor with mAb04c and lysozyme; (3) washed mAb04c crystals from 
mother liquor with lysozyme; (4) the supernatant from the crystallization with lysozyme; 
(5) mother liquor with mAb04c and BSA; (6) washed mAb04c crystals from mother liquor 
with BSA; (7) the supernatant from the crystallization with BSA. 
    
     With the success of the HCP spiking test, we attempted to purify mAb04c from the 
culture supernatant through one-step crystallization. The supernatant was conditioned and 
concentrated by diafiltration / ultrafiltration and centrifugation as described above. The 
volume of crystallization suspension was scaled up from 2 µl to 40 µl in a Crystalbridge™ 
(20 µl protein solution plus 20 µl reservoir). The reservoir was also scaled correspondingly 
to 20 ml to keep the ratio constant.  
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Figure 10. Micrograph of crystalline mAb04c crystallized from clarified culture 
supernatant. Crystallization condition: sitting drop. Reservoir: 0.1 M imidazol, 0.2 M 
calcium acetate, 9 % w/v PEG 8000. 20 µL clarified culture supernatant (8.3 mg/ml 
mAb04c) plus 20 µl reservoir, RT. Scale bar 100 µm. 
 
     Similar to results of the HCP spiking test, crystals became visible after 2 days (Figure 
10). After 5 days the harvested crystals were redissolved in 20 µl 100 mM Sodium Acetate 
pH 4. On SDS-PAGE using Coomassie staining (Figure 11), the concentration of 
contaminating proteins was considerably reduced (lane 2). A sample of IgG purified by 
protein A chromatography is shown as a benchmark reference (lane 3). The purity and 
amount of mAb in each fraction was then accessed by HPLC-SEC (Table 4). Before 
crystallization, the purity of mAb04c in solution (8.3 mg/ml in 20 µl supernatant) was 42 
% of total protein according to peak integration. The analysis of redissolved crystals (2.6 
mg/ml mAb in 20 µl buffer) showed that no significant oligomer arose from crystallization 
(Figure 12). The purity was increased significantly to 90 % of total protein. Still, only 31.3 
% of the mAb originally present in the culture supernatant was recovered in crystals, while 
the larger portion (67.5 %) was still found in the crystallization supernatant. In comparison, 
the yield of crystalline mAb04c that had undergone a prior protein A purification was 95 % 
with no detectable product in the mother liquor. 
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Figure 11. Coomassie blue stained none-reducing SDS-PAGE of mAb04c before and after 
crystallization or protein A purification. 7 µg of IgG was loaded per lane.  Lanes: (1) 
clarified mAb04c culture supernatant; (2) washed mAb04c crystals, redissolved in 100 mM 
sodium acetate pH 4.0; (3) mAb04c, purified via protein A chromatography. 
 
Table 4.  Purity and Recovery of crystallized mAb04c 
Fraction 
Amount of mAb04c 
(µg) 
Recovery (%) 
Purity  
(%, estimated) 
Clarified culture 
supernatant 
166 100 42 
washed mAb 04c 
crystals
*
 
52 31.3 90 
supernatant from 
the crystallization 
112 67.5 10 
* Protein redissolved in 100 mM sodium acetate pH 4.0 
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Figure 12. SE-Chromatogram of the sample before and after crystallization. Elution buffer: 
0.05 M Tris/0.15 M NaCl, pH 7; flow rate: 1 ml/min; wavelength: 225 nm. (A) Clarified 
mAb04c culture supernatant. Peak 3: mAb04c, 8.42 min; Peak 4: Contaminating Protein, 
9.98 min; Peak 5: Histidine in buffer, 12.19 min. (B) washed mAb04c crystals, redissolved 
in 100 mM sodium acetate pH 4.0. Peak 2: mAb04c, 8.43 min. 
 
     The binding ability of mAb04c to protein A before and after crystallization was 
determined via Biacore
®
. The association rate constants (ka) were compared to evaluate a 
potential affinity loss. Before crystallization, ka was determined to 3.35×10
6
 L/ (mol*s), while 
after crystallization ka was 4.81×10
6
 L/ (mol*s). Apparently, crystallization had no 
influence on the affinity of the Fc-Region for protein A.  
Publications & Manuscripts 43 
 
 
     In spiking experiments, T7 bacteriophage and chromosomal DNA were added to the 
mAb solution before crystallization in order to challenge the ability of the crystallization 
process to remove non-protein impurities. Results are summarized in Table 5. LRV (Log 
reduction value) was 1.4 for DNA and 2.2 for T7 phage.  
Table 5.  Results of DNA and phage spiking 
 
Spiking 
concentration 
Concentration in 
re-dissolved 
crystals 
LRV 
T7 phage 
[PFU/mg mAb] 
6.4 x 10
7
 4.5x10
5
 2.2 
DNA       
[µg/mg mAb] 
25 1.1 1.4 
 
     In the present work, we examined the possibility of establishing crystallization as a 
process step for purification and formulation of a monoclonal antibody. High yields were 
achieved when crystallization was introduced after chromatographic purification, but not 
when conditioned cell culture supernatant was used as starting material. Interestingly, 
crystallization from culture supernatant was nevertheless possible and resulted in efficient 
removal of contaminants. 
       We frequently observed that within the crystallization region (area labeled by triangles 
in Figure 8), protein initially precipitated directly after mixing (Figure 13a), while crystals 
were detectable under the microscope only after a 3-4 hour lag period (Figure 13b & 
Figure 13c). This effect is known from literature. Even when the crystalline form of protein 
is more stable than its amorphous form, slow nucleation can delay the formation of crystals 
with respect to amorphous precipitate [18, 19]. Precipitate concentration will then decrease 
at the same time as crystals grow. Two models have been proposed to explain the growth 
of crystals from precipitates: phase transition and Oswald ripening [20]. Phase transition is 
a process where crystals form at the expense of a solid amorphous phase, whereas Oswald 
ripening describes growth of a few crystals at the expense of many microcrystals [21]. Ng 
et al. [20] reported that both processes can occur simultaneously. Unfortunately, the 
birefringence method described above is not applicable to microcrystals smaller than the 
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microscope resolution limit. In lack of a method distinguishing between amorphous 
precipitate and microcrystals, we could not decide which of the above processes was 
dominant. 
 
Figure 13. Time course of microbatch crystallization. Protein: 8 mg/ml mAb04c, 
crystallization buffer: 8 % (w/v) PEG 8000, 0.2 M calcium acetate 0.1 M imidazol, pH 7.0, 
RT. Time after mixing: (A) 0 hrs, (B)  2 hrs, (C) 10 hrs, (D) 70 hrs. Scale bar 100 µm. 
 
     To our knowledge, this is the first determination of the solubility limit at equilibrium for 
an IgG protein. Ahamed et al. [9] describe an apparent solubility limit in a system where 
precipitate, but not crystals formed. In comparison to their findings, we found a much 
lower solubility limit. This could of course be attributed to using a different protein, but 
Ahamed et al. point out that they would expect a lower solubility limit at equilibrium, i.e. 
in the presence of crystals as opposed to precipitate. The same antibody was studied by 
Lewus et al. [10] recently, and crystallization conditions were now identified at a different 
pH. However, here the solubility limit was not determined unequivocally as concentrations 
measured in the supernatant decreased over the course of 2 months (Figure. 4 of above 
reference). The large gap found in our experiments between equilibrium solubility and 
zone of spontaneous crystallization appears unexpected at first sight, but might be a feature 
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of IgGs in general. However, similar studies on other model antibody systems will have to 
be performed before this view can be corroborated. From a practical point of view, our 
result means that in a continuous process using heterogeneous nucleation, protein should 
be crystallizable at much lower protein concentration such as 2 mg/ml and at precipitant 
concentrations of 7 % PEG 8000 or even lower. 
     Removal of protein contaminations and virus was successful and comparable to Protein 
A chromatography. DNA removal however was marginal. This may be due to adsorption 
of DNA to the crystal surface by electrostatic interaction (mAb04c is positively charged at 
the pH of crystallization). We found that reducing the spiking concentration to 2.5 µg 
DNA/mg mAb, resulted in 0.35 µg DNA/mg mAb (data not shown), i.e. in an even lower 
LRV. 
     Recovery yield of crystallized mAb that had undergone prior protein A purification 
reached 95 %. This is expected when crystallization conditions are far above the solubility 
limit as revealed by the phase diagram. However, such high yields could not be achieved 
when cell culture supernatant was subjected to crystallization. Here the recovery of ~30 % 
indicated that either solubility of mAb had dramatically increased due to other compounds 
present in the culture supernatant, or crystallization had simply slowed-down. Microscopic 
examination indicated that onset of crystal formation was significantly delayed when 
culture supernatant was used instead of purified antibody: in the latter case, crystals could 
already be detected after 10 hrs, whereas the same process took 48 hrs starting from culture 
supernatant. Still, crystal shapes were similar in both cases.  
     Significant nucleation is the primary requirement for crystal formation. The nucleation 
rate depends in principle on the solubility of the protein, the degree of supersaturation and 
the interfacial free energy (?) between solute and solution [22]. The first two contributions 
are not expected to be significantly influenced by the presence of impurities. As for the 
interfacial free energy, from thermodynamic aspect, an increase of the nucleation rate 
should be observed when impurities are present in the solution [22], because any 
adsorption onto the nucleus decreases ? [23]. However, kinetically, adsorbing impurities 
can keep the nucleus at a subcritical size [22]. The nucleation rate hence can be drastically 
reduced. It was reported that impurities present at 10
-5
 mol/L can decrease the nucleation 
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rate by ten orders of magnitude [24]. Biostelle et al. [22] point out that there is a 
competition between the adsorption kinetics of the impurities and the adsorption and 
integration kinetics of the solute, hence, a longer nucleation time is needed.  
     Moreover, this competition may further affect the growth of crystals when nuclei 
develop and begin to transform into crystals. Impurities can adsorb to the surface of the 
growing crystal, inhibit the addition of free molecules and thereby decrease the growth 
rate. Because of the negative effect of impurities in both stages of crystallization, the 
observed delay in mAb04c crystal formation in the presence of contaminating protein was 
not unexpected. In our work we did not study which stage was prone to be affected by the 
presence of impurities. 
     A low recovery rate (31.3 %) was observed, when mAb04c was crystallized from 
culture supernatant. In a future scaled-up process, nucleation and crystallization rates will 
have to be controlled e.g. by seeding, feeding protein during crystallization or evaporating 
solvent. Therefore the yield currently obtained should be subject to significant 
improvement when working at larger scale. 
 
Conclusion 
Protein crystallization has the potential to be introduced as a purification step in 
downstream processing of mAbs, although our present results so far show that it will likely 
be more useful in a later purification step and not in initial capturing of the product. Here 
we demonstrate purification of a monoclonal antibody in a single crystallization step from 
clarified cell culture supernatant to > 90 % purity, though with yet unsatisfactory yield. 
Aggregate formation was negligible as shown by SE-HPLC and binding activity to Protein 
A was not affected by crystallization. The current crystallization time of several days 
required to reach equilibrium is partly due to the shortcomings of vapor diffusion and 
should be subject to considerably improvement in a seeded batch process. Current work is 
focused on up-scaling and optimization of the process with respect to higher yields. We are 
well aware that at present only a handful of intact IgGs have been successfully crystallized 
and that there is no generic method available to identify crystallization conditions rapidly 
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for new antibodies. However, the recent results of Lewus et al. [10], who were able to 
crystallize an antibody where previously no crystallization conditions have been found [9], 
are encouraging. More work on a larger set of target mAbs will have to be done before the 
usefulness of this method can be evaluated in a broader context.  
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Abstract 
Large-scale crystallization of pharmaceutically active antibodies has been considered as a 
possible purification step, and feasibility at small scale has been demonstrated for a 
number of cases. Here we investigate the robustness of crystallization with regard to the 
presence of different unrelated proteins over a wide concentration range. Spiking 
crystallization batches with four model proteins reveals considerably different influences 
on the time course and yield of antibody crystallization: Protein impurities showing 
attractive interactions with the antibody in solution as detected by static light scattering 
analysis inhibit crystal growth at much lower concentration than proteins exhibiting 
repulsive interactions. At the crystallization condition used, electrostatic properties most 
likely dominated these interactions and could be used to predict the influence of the 
impurities on crystallization. The results provide important hints on process operations that 
should be implemented in downstream processing prior to a crystallization step. 
Key words: impurity, protein crystallization, antibody, electrostatic interaction  
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Introduction 
Therapeutic antibodies have seen an enormous success since first introduced in 1986, with 
currently about 30 antibody drugs approved for the US market [1]. When compared to 
small-molecule drugs, production of recombinant antibodies is much more costly. It has 
been estimated that up to 90 percent of the total production cost is taken up by the 
downstream process, where proteins are purified by chromatographic and filtration 
methods. Competition and the rise of biosimilars have started to exert strong economic 
pressure onto manufacturers who are evaluating alternative, more economic purification 
methods. Crystallization at industrial scale has recently attracted increasing interest as a 
possible alternative that might replace at least one chromatography unit operation [2, 3]. In 
our own work [4], we determined the phase diagram of an IgG that crystallized at low 
ionic strength in the presence of polyethylene glycol (PEG). However, in this system, both 
the crystallization rate and the final yield strongly depended on the purity of the starting 
material: If the antibody was purified by protein A chromatography prior to crystallization, 
crystals formed rapidly and high yields of crystalline protein were obtained reproducibly. 
If, on the other hand, the antibody was crystallized directly from concentrated cell culture 
supernatant low yields paralleled by slow crystal growth were observed.  
     Most of the published work on protein crystallization has been conducted with X-ray 
structure analysis in mind, where single, well-diffracting crystals are critical for success, 
while yield and scalability are of minor concern. The single most important factor affecting 
protein crystallization is certainly the target protein to be crystallized. However, all 
compounds other than the product can also affect growth rate and crystal yield when 
present in the starting material. Beneficial or deleterious effects of impurities on crystal 
growth are well documented in the case of small molecules [5, 6]. For macromolecular 
crystallization, the effect of impurities has been mostly studied on model proteins such as 
lysozyme [7-10], due to its easy access and crystallizability. Nevertheless, results from 
lysozyme cannot always be transferred to other proteins [11].  
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     The protocol established in our paper cited above [4], allowed to crystallize the intact 
monoclonal antibody (mAb) mAb04c at micro liter scale over a period of two days 
yielding 95 % of crystalline mAb. When concentrated cell culture supernatant instead of a 
protein A eluate was used as the starting material, crystal yield and growth rate dropped to 
30 % after 5 days of crystallization. The cell culture supernatant contained a significant 
fraction (~60%, w/w) of contaminating proteins including product-related impurities as 
evidenced by SE-HPLC.  In the present report, we asked which properties of protein 
impurities might be responsible for inhibiting the crystallization process. To answer this 
question, we measured crystallization kinetics in the absence and presence of defined 
spiking proteins at varying concentrations, and at the same time investigated interactions 
between target protein (mAb) and protein impurities using light scattering. We explored a 
broad range of contaminant-to-product ratios that covers representative samples of cell 
culture supernatants used in industrial processes. 
   
Materials and Methods 
Antibody 
Protein A-purified mAb04c (purity > 98 %), a monoclonal IgG4 type antibody derived 
from a CHO cell line was kindly provided by Boehringer Ingelheim Pharma GmbH 
(Biberach, Germany).  
Sample preparation 
 Protein A-purified mAb was concentrated to the desired concentration in 50 mM Histidine 
buffer pH 7.0 with Vivaspin™ 500 centrifugal filter (30 kDa MWCO, Sartorius, Germany) 
by centrifugation (15000g, 4°C). Concentration of purified mAb was determined 
photometrically at 280 nm using a mass extinction coefficient of 1.47 [ml/ (mg?cm)]. 
Crystallization technique 
Crystallization was carried out as described previously [4] using optimized conditions. 2.7 
mg/ml (18 µM) mAb04c with and without added macromolecular impurities was 
crystallized in 25 mM Histidine, 25 mM Tris, 3.15 % (w/v) PEG 3350, pH 7.2 at room 
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temperature (ca. 21 ?C).  Protein was crystallized in parallel at micro batch (? 10 µl) as 
well as at batch (1 ml) scale. All mixtures were seeded by adding crystalline mAb04c to a 
final concentration of 2µg/ml to prevent nucleation processes from dominating the 
kinetics.  
Spiking experiments with unrelated proteins  
The effect of impurities on crystallization was investigated by spiking the crystallization 
batches with defined unrelated proteins at the molar ratios (spiking protein: mAb) 
indicated. Dependence of crystal yield on the concentration of added bovine serum 
albumin (BSA, Sigma, Germany) after 10 and 20 hours of crystallization, respectively, was 
investigated over a molar ratio range (BSA: mAb) of 0.29 to 7.7. Next, the antibody was 
crystallized in the presence of one out of four proteins (ovalbumin, lysozyme, cytochrome 
c, BSA) at a constant molar ratio of 3.7. Lysozyme, ovalbumin and cytochrome c were 
from Fluka (Switzerland).  
     1 ml batch experiments were carried out in 1.5 ml reaction tubes (Eppendorf, Germany) 
and were agitated in a test-tube rotator during the entire procedure. For visual inspection 
under microscope, 3 µl aliquots were withdrawn from each batch and transferred to 
microbatch plates (Greiner Bio-one, Germany). Crystallization rates were determined by 
measuring the time course of antibody concentration in the supernatant: 30 µl samples 
were taken from batch experiments at defined intervals and centrifuged at 15,000 g, 10 °C 
for 10 min. The supernatant was diluted with 120 µl of distilled water to prevent further 
crystallization. The IgG concentration in the samples was determined by Protein-A-HPLC 
on an HP1100 HPLC system (Agilent, Waldbronn, Germany) equipped with a pre-packed 
POROS® Protein A affinity column and a 1 mm guard column (Applied Biosystems, US). 
The equilibration buffer was 25 mM sodium phosphate 150 mM NaCl pH 7.4, the elution 
buffer was 25 mM sodium phosphate pH 3.0, the flow rate was 1 ml/min. Chromatograms 
were recorded at 225 nm, elution peaks integrated using the Chromeleon
®
 software 
(Dionex, Sunnyvale, US) and compared to a mAb standard. The protein composition in the 
supernatant was analyzed by non-reducing SDS-PAGE on 12.5 % Laemmli gels and 
staining with Coomassie Blue.  
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Characterizing of protein-protein interaction via composition-gradient multi-angle 
static light scattering  
Osmotic virial coefficients were determined as an indicator of attractive or repulsive 
interactions between product and contaminant. Composition gradient-multiangle static 
light scattering (CG-MALS) allows to measure self-virial coefficients (SVC) A2 and the 
cross-virial coefficient (CVC) A11 for a two-component system simultaneously. A2 
describes interactions between molecules of the same type (i.e. mAb or impurity, 
respectively), while A11 describes the interaction between two different molecules. Positive 
virial coefficients are indicative of repulsive, negative coefficients of attractive interactions.  
     In CG-MALS, static light scattering intensity is measured as a function of protein 
concentration. For a two-component system, the concentration gradient has to be designed 
so that both SVCs of the individual components and the CVC can be extracted [12-14]. A 
Calypso
™
 II System for sample preparation and delivery connected to a Dawn-8
® 
multi-
angle static light scattering detector and an Optilab T-rEX
™
 refractive index (RI) detector 
for the determination of protein concentration were used. Instruments were from Wyatt, 
CA, USA. 
     All proteins were dissolved or diluted in buffer containing 25 mM Tris, 25 mM 
Histidine, pH 7.2 as stock solution, where mAb04c concentration was 2 mg/ml, and the 
concentrations of BSA and lysozyme were 6 mg/ml. All protein samples and buffer were 
filtered through 0.2 µm syringe filter (Sartorius, Germany). The mAb04c solution was 
mixed with BSA or lysozyme solution by the Calypso
™
 II System. Different compositions 
were obtained by varying the relative flow rates of the pumps and then injected into the 
SLS and RI detectors. Three segments were integrated in the programmed method (Figure 
14, mAb04c and BSA as an example): a concentration gradient of mAb alone, followed by 
a crossover composition gradient changing the ratio of concentration of mAb and BSA, 
and finally a concentration gradient of BSA.  
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Figure 14. Experiment design for the characterization of nonspecific interaction between 
mAb04c and BSA using CG-MALS. Running buffer: 25 mM Tris, 25 mM Histidine, pH 
7.2. The mAb04c solution was mixed with BSA solution by the Calypso
™
 II System: a 
concentration gradient of mAb alone, followed by a crossover composition gradient 
changing the ratio of concentration of mAb and BSA, and finally a concentration gradient 
of BSA. Both protein solutions were conditioned in running buffer. Blue line: 
concentration gradient of mAb04c; Red line: concentration gradient of BSA. 
 
     The other two spiking proteins, cytochrome c and ovalbumin, were not amenable to 
CG-MALS analysis. Cytochrome c absorbs light at the wavelength of the incident laser 
light (658 nm). Ovalbumin appeared to form large soluble aggregates in the running buffer: 
SLS analysis indicated an apparent molecular weight of ~ 350kDa instead of the expected 
44 kDa, although the protein solution appeared clear. Both effects interfere with light 
scattering analysis.  
     Molecular weight, SVC and CVC were determined fitting the measured scattering 
intensities to equation (7) [15]: 
 ? ??? ??? ? ? ??????? ?????? ???????? ? ?????????? ??????? ? ? ??????? ?????? ???????? ? ?????????? ???? ??? ?? ? ? ?????? ? ???????????????????? ????? ??? ???? ???????????????????????? 
 
in which R(c, ?) is the excess Raleigh ratio at the angle ? (the angle between the scattering 
direction and the incident light); K is a constant that depends on the wavelength of incident 
light and solvent refractive index; dn/dc is the sample refractive index increment; and P (rg, 
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?) is the angular dependence of the scattered light on rg, the radius of gyration of the 
sample; the indices A and B represent the two different proteins.  
 
Results 
Crystallization at varying impurity concentration 
MAb04c was crystallized in seeded batch experiments as described in Methods in the 
absence and presence of added protein impurities. Figure 15 shows the dependence of 
crystal yield on the concentration of added bovine serum albumin at two time points.  Pure 
antibody was crystallized to 95 % after 10 hours and to 98% after 20 h. Increasing the BSA 
concentration slowed down crystal formation considerably. At a molar ratio of BSA to 
antibody of 0.77 no crystals were visible after 10 h, while after 20 h, more than 90 % had 
crystallized. At a ratio of 7.7, no crystals formed even after 20h. Micrographs (Figure 16) 
confirm that insoluble protein was always crystalline and never amorphous.  
 
Figure 15. Influence of BSA amounts on the crystallization process of mAb04c. MAb04c 
was crystallized with BSA at molar ratios (BSA: mAb) of 7.7, 4.5, 2.9, 2.3, 0.77, 0.45, and 
0.29. Fraction of crystallized mAb in each sample was determined after 10hrs and 20hrs.  
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     To control whether crystals were formed from antibody and not from the spiking 
protein, supernatant samples were subjected to SDS-PAGE. In Figure 17, the staining 
intensity of antibody in the supernatant decreased during crystallization while the intensity 
of the BSA band remained constant as expected. Although an incorporation of BSA in the 
mAb-crystals cannot be totally excluded, this result indicates that the crystals 
predominantly originated from antibody, even at a molar excess of BSA over mAb of 3.7. 
 
 
Figure 16. Optical micrographs of micro batches with BSA as examples of growth of 
protein crystals after a period incubation. Top left: initial conditions in batches, the black 
dots were seeds of mAb04c. Top right: in section of the batch with molar ratio of 0.29 after 
incubation of 20 hrs. Bottom left: inspection of the batch with molar ratio of 4.5 after 
incubation of 20 hrs. Bottom right: same sample as that in the bottom left, but with a 
higher magnification, the aggregate showed slight birefringence under polarized light 
demonstrating the protein crystalline. Scale bar in the top left, top right and bottom left 
=200 µm, 100 µm in the bottom left. 
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Figure 17. Time course of protein concentration in the supernatant of a batch with BSA 
(molar ratio 0.29) as impurity. 6.4 µl samples of supernatant after centrifugation from 
batch experiments were loaded. The staining intensity of BSA remained constant, while the 
intensity of mAb04c decreased over time, indicating that the observed crystals resulted 
from mAb04c. The skewed band of BSA at 5 hours could be caused by uneven gel. 
 
Crystallization kinetics in the presence of different spiking proteins  
Following this first experiment, four model contaminants representing a range of different 
molecular weights and isoelectric points (Table 6) were mixed with mAb04c in separate 
batches. The molar ratio was 3.7 throughout the experiments.  
Table 6. Molecular weights (MW) and isoelectric points (pI) of mAb04c and the spiking 
proteins. 
 Molecule MW, kDa pI Resource 
mAb04c 150 8.2-8.5 kindly provided by Boehringer Ingelheim 
BSA 66 4.7 Malamud D and Drysdale JW, 1978 [16] 
ovalbumin 44 4.4-4.6 Beeley JA et al. 1972 [17] 
lysozyme 14.3 10.7 product information 
cytochrome c 12.3 10.6 Keilin D and Hartree EF, 1945 [18] 
 
     The time courses of crystallization are presented in Figure 18. In the presence of 
lysozyme and cytochrome c as well as in the control experiment without contaminant the 
main decrease of mAb04c concentration in the supernatant occurs in a period of 3 to 5 
hours after mixing. Equilibrium (ca. 0.25 mg/ml) is reached after 10 hours. Crystallization 
batches containing ovalbumin or BSA precipitated immediately after mixing, which 
resulted in lower mAb-concentrations in the supernatant during the first 5 hours compared 
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to the other batches. However, precipitate later dissolved and mAb concentration in the 
supernatant increased again for the next 5 hours. Time to equilibrium was about 22 hours 
for the batch containing ovalbumin and about 30 hours for the batch containing BSA. 
 
Figure 18. Time courses of mAb concentration in the supernatant of batches with and 
without the spiking proteins. Molar ratio (spiking protein: mAb) was 3.7. At this molar 
ratio, crystallization of mAb04c was suppressed in the first 10 hours by the presence of 
ovalbumin and BSA, whereas no obvious inhibition was found by lysozyme and 
cytochrome c. 
 
Interactions between antibody and the spiking proteins in solution  
As shown in Figure 18, two proteins (lysozyme and cytochrome c) had only a very small 
effect on crystallization kinetics, while the other two considerably slowed down the 
process. We speculated that inhibition of crystallization could be due to adsorption of the 
contaminant protein to the surface of growing crystals. To investigate the interaction of 
mAb and contaminant in solution, we performed CG-MALS experiments as described in 
the methods section. Figure 19 presents the analysis data for the determination of virial 
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coefficients using CG-MALS. In Zone II, mAb04c was mixed with spiking protein at 
different ratio to investigate the CVC. The fitted results of the MALS data are presented in 
Table 7. Analysis of the data yields a CVC value A11 of +2.94E-4 mol? ml/g2 for mAb04c-
lysozyme system and -1.19E-4 mol? ml/g2 for mAb04c-BSA system.  
 
Figure 19. Analysis data from CG-MALS for the determination of virial coefficients. Solid 
line: light scattering signal; dashed line: concentration signal. Three segments were 
incorporated in each experiment: a concentration gradient of mAb04c alone (zone I), 
followed by a crossover composition gradient changing the ratio of test proteins (zone II), 
and a concentration gradient of BSA in A and lysozyme in B (zone III). All components 
were conditioned in 25 mM Tris, 25 mM Histidine, pH 7.2. Duration before 1000 s was 
preparation phase and was thus not shown here.  
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Table 7. Fitting results of the CG-MALS data. A2 is the second self-virial coefficient. A11 
is the cross-virial coefficient. The negative A11 in mAb04c-BSA system indicated 
attractive interactions between mAb04c and BSA molecules, and the positive A11 in 
mAb04c-lysozyme system suggested repulsive interactions between mAb04c and 
lysozyme. 
 
mAb04c-BSA System mAb04c-lysozyme System 
mAb04c BSA mAb04c Lysozyme 
A2 (SVC) +1.81E-4 +1.83E-4 +1.32E-4 +1.52E-3 
A11 (CVC) -1.19E-4 +2.94E-4 
 
Discussion 
In the hierarchy of parameters governing growth of protein crystals, purity and 
homogeneity are amongst the most important [7, 19, 20]. For soluble proteins, a large-scale 
study [21] demonstrated that 229 proteins with purity levels of more than 95 % could be 
crystallized in 59% of all instances, whereas for protein samples exhibiting less than 95% 
purity the crystallization success rate was reduced to 37%. The yield of crystalline protein 
was not determined in this study, though. As a consequence, the ratio of contaminant to 
product is a critical factor in protein crystallization and has to be carefully controlled in an 
industrial process. In our present work, we investigate molar ratios of contaminant to 
mAb04c ranging from 0.29 to 7.7, which corresponds to a purity of mAb04c between 23% 
- 89% (w/w total protein).  In comparison, the purity of mAb04c in culture supernatant was 
40% according to SE-HPLC [4]. The purity range of our experimental setup therefore 
addresses crystallization at an early stage in the downstream process.  
     As expected, the presence of macromolecule impurity elicited an inhibitory effect on 
mAb04c crystallization in a concentration-dependent manner. Impurities can adsorb to the 
surface of a growing crystal and impede the addition of desired components [22-25]. 
Indeed, even when the mAb04c to BSA ratio was still about 3 (a molar ratio of 0.29 in 
Figure 15), crystal growth rate had decreased significantly. Adsorption of the impurity to 
active growth sites on the crystal are a likely explanation, as reported previously for small 
molecules [25]. On the other hand, if the impurity concentration exceeds that of the target 
protein (e.g. molar ratio >4.5 in Figure 15), crystallization could also be slowed down by 
reduced mass transport of the target protein from the bulk solution to the crystal surface. 
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This would be the case if target protein and impurity interact in solution. For BSA and 
ovalbumin, the latter might be the dominant effect. 
     Interestingly, the strong inhibition was not observed if crystallization of mAb04c was 
spiked with lysozyme or cytochrome c at a molar ratio of 3.7. Experiments similar to 
Figure 15 showed that notable inhibitory effect of lysozyme or cytochrome c only started 
at a molar excess of ten with respect to mAb04c (data not shown). Consequently, some 
mechanism appears to prevent these two proteins from inhibiting growth of crystals.  
     The negative CVC value of the mAb-BSA versus the positive CVC value of the mAb-
lysozyme system indicates a strong attractive interaction between mAb and BSA, but a 
repulsive interaction between mAb and lysozyme in the crystallization buffer. This 
difference is most likely a consequence of the respective isoelectric points of the proteins 
investigated (Table 6) and their resulting charge: mAb04c attracts BSA because of its 
opposite overall charge at pH 7.2, while mAb and lysozyme carry even charges and 
therefore repel each other. As the crystal’s surface potential carries the same sign as the 
crystal forming molecule, attractive and repulsive interactions between growing crystal and 
soluble contaminant are expected to be the same as in solution. Also, at the low ionic 
strength used in our crystallization condition, electrostatic effects will not be attenuated. 
The crystallization kinetics in the presence of contaminants can therefore be mostly 
explained by electrostatic interactions between contaminant and target protein.  
     At very high excess concentration of lysozyme or cytochrome c, crystal growth might 
be impaired by a more viscous solution, leading to decreased diffusion rates and decreased 
mass transfer to the crystal surface. 
     A practical consequence of our finding is that a process step able to remove compounds 
interacting strongly with the product in solution should precede crystallization. For the 
system investigated here this could be an anion exchange chromatography operated in 
flow-through mode, which would remove only contaminants of opposite charge. This step 
would be fast to implement and not require much fine-tuning.  
     To our knowledge, the present report is the first describing inhibition of crystallization 
caused by electrostatic interactions. We are well aware that under different crystallization 
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conditions, such as the use of ionic precipitants, other interactions might become dominant. 
Even there the interaction analysis in solution might be a useful tool for designing a 
process step that enhances subsequent crystallization  
Conclusion 
In this work, we investigated how crystal growth of an intact monoclonal antibody is 
affected by protein impurities. The results suggest that the molar ratio of impurity to 
product as well as the interaction between product and impurity in solution were the two 
most important factors affecting crystallization kinetics and yield. The slowdown of 
crystallization rate was correlated with molar ratio of impurity to target protein, which was 
within expectation. Protein impurities with the same charge prefix as the product showed 
only minor inhibitory effects, probably due to electrostatic repulsion from the crystal 
surface. This might explain why some impurities influence crystallization at excess 
concentrations below 1 ppm, whereas others have to be present at fairly large 
concentrations before showing any effect [26, 27]. Interactions in solution as measured by 
SLS correlated with the inhibitory effect on crystallization. Whether this method has 
general predictive power will have to be shown by using the same approach for other 
proteins and crystallization conditions.  
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Abstract 
Seeded fibrillation of hen egg-white lysozyme at low pH was established as a model 
system of protein aggregation. The stabilization potency of osmolyte additives was tested 
using fluorescent dyes. The experimental setup allowed determining both shifts of the 
protein melting point Tm as well as aggregation kinetics under identical solvent conditions. 
A set of 21 compounds representing the three known osmolyte substance classes (polyols, 
amino acids and methylamines), was chosen and their thermal and kinetic stabilizing 
potencies were determined as a function of osmolyte concentration. A correlation of both 
stabilizing effects was clearly distinguishable, but so were deviations from perfect 
correlation. In general, polyols increased both thermal and kinetic stability in a 
concentration-dependent manner while most compounds of the amino acid and 
methylamine groups lead to destabilization. An attempt to correlate the observed 
stabilization effects with molecular mass and pKa values of the compounds revealed some 
weak structure function relationships. We tentatively interpreted our data by a volume 
exclusion effect dominating in the case of added polyols, while preferential binding 
appears to be responsible for destabilization by amino acids and methylamines. It also 
becomes evident that additional molecule-specific properties influence the stabilization 
potency of compounds tested. Additional model systems allowing controlled formation of 
different types of aggregates and larger sets of stabilizers should reveal information that 
could be used to design novel molecules that surpass the stabilizing properties of naturally 
occurring osmolytes.  
Keywords: osmolyte, melting point, fibrillation, thermal stability, kinetic stability, 
lysozyme, ThT 
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Introduction 
   Aggregation of industrially produced proteins is a major problem resulting in activity 
loss and, in the case of pharmaceutical proteins, in safety issues due to immunogenic 
adverse reactions. It is therefore good practice to take measures during the downstream 
process to prevent aggregate formation and to remove aggregates [1].  The situation is 
complicated by the fact that aggregation can follow different pathways that may or may not 
include structural changes of the protein molecule. Examples of aggregation processes 
include precipitation by salting-out (reversible, structure is preserved), fibrillation in 
neurodegenerative diseases (irreversible, structure changes to beta-sheet), spontaneous 
aggregate formation during storage of biopharmaceuticals (reversible or irreversible, may 
include structural changes) etc. [1, 2]. Often, a rate-limiting step at the early onset of 
aggregation is the formation of nuclei, rendering this process highly auto-catalytic. 
Therefore, considerable effort is made to remove even trace amounts of aggregates, which 
otherwise would reduce stability and shelf-life of purified proteins. 
    Storage solvents for proteins are optimized not only by varying pH and ionic strength, 
but also by exploring the stabilizing effect of excipients added to the solvent. Among those 
is the group of osmolytes, naturally occurring, small organic molecules that many species 
have evolved in order to cope with osmotic, heat or desiccation stress [3]. The majority of 
osmolytic compounds belong to three substance classes: polyhydric alcohols and sugars 
(polyols), amino acids and their derivatives and methylamine compounds [3]. Most of 
these compounds have been shown to increase thermal stability of proteins as reflected by 
a shift of Tm, the midpoint of the unfolding transition, to higher values [4-8]. Those 
protecting osmolytes are presumed to act by their preferential exclusion from the protein 
surface, thus favouring compaction of the protein. From a thermodynamic point of view, 
the denatured state is at a higher Gibbs potential in the presence of osmolytes than in their 
absence, resulting in an increase of the Gibbs free energy of unfolding [8, 9] and therefore 
in higher protein stability.  
    The effect of osmolytes on thermal stability has been studied extensively [3-6, 8, 10, 
11]. However, increased thermal stability does not necessarily correlate with extended 
shelf life of protein products. The latter can result partially or completely from kinetic 
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inhibition of aggregation and has a large impact in industrial applications. It is less clear, 
which of the osmolyte compounds can also act as kinetic stabilizers, i.e. inhibit or slow 
down protein aggregation. In some reports, this question has been addressed: Osmolytes 
were able to slow down insulin fibrillation [12] or to increase the storage half-life of 
human recombinant growth factor [6]. However, we are not aware of any systematic 
studies correlating thermal and kinetic stabilization by osmolytes.  
    Under some experimental conditions, osmolytes can even exhibit protein-destabilizing 
properties (reviewed in [13]). One parameter strongly influencing whether an osmolyte 
reacts in a protective or denaturing way is the solvent pH: For instance, TMAO is a potent 
stabilizer at neutral pH but destabilizes proteins at low pH [14]. A similar ph-dependency 
has also been reported for glycine betaine on ?-lactalbumin [15]. Also polyols, while 
showing no influence on protein stability at pH 7.0 were able to increase ?GD0 at low pH 
values [16]. Protein destabilization may as well occur at very high osmolyte concentrations 
[5, 17], where the modestly favourable interactions between apolar parts of the osmolyte 
and hydrophobic side chains become more significant, resulting in exposure of 
hydrophobic residues and unfolding [5]. Finally, part of the action of osmolytes can be 
protein-specific: The strength of protection from thermal denaturation can vary as different 
physico-chemical properties between the studied proteins lead to differences in protein-
solvent interaction [18]. That is, opposite effects have been reported for glycine betaine 
depending on the examined protein: While the osmolyte exhibits destabilizing properties 
on ?-lactalbumin at pH values below 5.0, Tm and ?GD0 of RNase A are instead increased at 
equal or even lower pH values [15].  
    Destabilizing effects have been attributed tentatively to preferential binding of the 
osmolyte to the protein surface and can lead to a reduction in the Gibbs free energy of 
unfolding [13]. However, the opposite may also occur, i.e. preferential binding can result 
in increased protein stability [19], depending on whether binding is energetically more 
favourable to the folded or unfolded state of the protein.  
    Previously published work often focuses on rather small sets of osmolytes, those 
compounds often belonging to different substance classes [6, 10, 11]. Conclusions about 
common effects within and differences between compound classes are difficult to draw 
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from those data, even if taken together, since experimental conditions such as pH, solvent 
composition and protein type critically determine the osmolytes' impact on stability. As a 
result, general effects tend to get hidden behind variations caused by different experimental 
setups. To overcome this problem, we decided to focus on a single model for protein 
aggregation, lysozyme, and to include 21 selected osmolytes from all three compound 
groups. Lysozyme can be transformed into fibrils under defined conditions [20], and the 
system can be manipulated to yield reaction kinetics amenable to high throughput 
measurements. Obviously, any conclusion drawn from our data might be specific for the 
test system used and doesn't have to apply for other proteins or other aggregation 
mechanisms. In addition to kinetic measurements, we also investigate the effect of the 
same osmolytes on Tm under identical solvent conditions to allow for comparison of 
thermodynamic and kinetic stabilization effects. Stabilization potential within a substance 
group is finally correlated with molecule characteristics (molecular weight (MW) and pKa 
value), revealing some weak structure function relationships.   
    In a similar study, we recently investigated the effect of 18 polyols, amino acids and 
methylamines on the kinetic stability of glucagon to understand how intrinsically 
disordered proteins were affected by osmolytes [21].  
 
Materials and Methods 
Preparation of protein and osmolyte solutions 
    A representative sample of 21 osmolytes was selected from Table 6.1 in Hochachka and 
Somero [22]. The selected compounds are listed in Table 8 and include compounds of the 
polyol, methylamine and amino acid classes of osmolytes. Choline-O-sulfate (COS) and 
proline betaine were synthesized according to Schmidt and Wagner [23] and King, 
respectively [24]. All other chemicals were purchased from AppliChem (Darmstadt, 
Germany) and Sigma-Aldrich (Taufkirchen, Germany) and were of the highest purity 
available.  
 
Publications & Manuscripts 72 
 
 
Table 8. List of included osmolytes 
  
Substance class Osmolyte Abbr.
1
Molecular weight  pKa value
2
Polyols Trehalose tre 342.3 g/mol  
Mannitol  man 182.2 g/mol  
Sorbitol  sor 182.2 g/mol  
Erythritol ery 122.1 g/mol  
Myo-Inositol  myo 180.2 g/mol  
Glucose glc 180.2 g/mol  
Glycerol glyc 92.1 g/mol  
Amino acids 
and derivatives 
Glutamine  gln 146.2 g/mol 2.15 
Proline  pro 115.2 g/mol 1.94 
Alanine  ala 89.1 g/mol 2.47 
Glycine  gly 75.1 g/mol 2.31 
Serine ser 105.1 g/mol 2.03 
Taurine  tau 125.2 g/mol -1.49 
Beta-alanine  ß-ala 89.1 g/mol 4.08 
Ectoine ect 142.2 g/mol 2.75 
Hydroxyectoine OH-ect 158.2 g/mol 2.48 
Methylamines  Betaine  bet 117.2 g/mol 2.26 
 Sarcosine  sarc 89.1 g/mol 2.06 
 Choline-O-sulfate COS 183.3 g/mol -1.88 
 Trimethylamine-N-
oxide  
TMAO 75.1 g/mol 4.66 
 Proline betaine pro bet 179.6 g/mol 2.26 
1
 Abbreviations are used in figure legends. 
2
 pKa values were calculated using Marvin [28]. 
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    Osmolytes were dissolved in 0.1 M glycine, pH 2.5 and pH value was adjusted to 2.5 
where necessary. All solutions were sterile-filtered with a 0.22 µm filter prior to use. 
    Hen egg white lysozyme (Sigma-Aldrich # 62971) was dissolved in 0.1 M glycine, pH 
2.5, and filtered as above. Protein concentration was calculated from A280 measurement 
using an extinction coefficient of 2.48 L·mol
-1
·cm
-1
.   
    For experiments at neutral pH, osmolytes and lysozyme were dissolved in 0.1 M sodium 
phosphate, pH 7.0 and treated as above.  
    Fibril seed stock was prepared by sonication: fibrillated lysozyme solutions (2 mg/ml) 
were subjected to sonication pulses of 50 % power for 3x10 s (Bandelin, Berlin, Germany, 
Sonopuls HD2070, sonotrode MS 72). Aliquots were stored until use at -20 °C. 
Fibrillation of lysozyme 
    Lysozyme fibrillation was induced on the basis of Morshedi et al. [20]. However, 
protein and seed concentration as well as temperature was optimized to shorten the time 
needed for complete fibrillation and to allow for high throughput experiments.  
    All experiments were carried out in triplicates in 96 well plates (Roche, Mannheim, 
Germany, #04729692001). 100 µl samples containing 5 mg/ml lyoszyme, 40 µg/ml fibril 
seed stock, varying concentrations of osmolyte and 40 µM ThT (Sigma-Aldrich, 
Taufkirchen) were incubated without agitation at 75 °C in a Roche LightCycler 480. ThT 
fluorescence was monitored over a time course of 100 hrs (excitation 450 nm, emission 
500 nm). Fluorescence reached a plateau in all experiments, which was used as endpoint 
for lag time calculations. No increased ThT fluorescence was observed when protein was 
omitted from the reaction, thus excluding the possibility of direct osmolyte-ThT-
interaction. 
    Due to its autocatalytic nature, fibrillation usually follows a sigmoidal time course [25]. 
Lag time, for our experiments defined as the time required to reach 5% of the fluorescence 
endpoint intensity, can be  used as an indicator of kinetic stability [12, 21, 26]. For some 
osmolytes (beta-alanine, TMAO and proline betaine), the sigmoidal curve shape could not 
be resolved even at the highest possible observation rate (one data point per 10 seconds). 
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For consistency, the 5% time point was used anyway as the lag time. The seed stock 
prepared as above apparently was not entirely stable, even when stored as frozen aliquots. 
We observed decreasing fibrillation lag times upon longer storage (data not shown). This 
problem was accounted for by including control experiments lacking osmolyte on each 
microtiter plate. For comparability, all results are presented relative to the control lag time 
on the same plate, the control lag time always set as 100 %.  
Differential Scanning Fluorimetry 
    Thermal stability was investigated by measuring melting points (Tm) using a slight 
modification of the method introduced by Niesen et al. [27]. Experiments were performed 
in triplicate on a Roche LightCycler 480 in 96 well plates. In a reaction volume of 50 µl a 
final concentration of 0.8 mg/ml lysozyme was mixed with varying osmolyte 
concentrations. SYPRO Orange (Invitrogen, Darmstadt, Germany, 5000x in DMSO) was 
diluted 1000 fold in the assay. Melting points were derived from the inflexion point of the 
melting curves. 
 
Results 
Kinetic measurement of lysozyme fibrillation 
    Induced fibrillation of lysozyme as described under Methods was used as a model 
system to investigate the influence of osmolytes on fibrillation kinetics. Fibril formation 
was monitored by fluorescence measurement of the fibril-specific dye Thioflavin T. For 
most experiments fluorescence followed a sigmoidal time course leading to a maximum 
value, confirming previously published results [25]. An "overshoot" of the curve as 
observed e.g. for glucagon fibrillation [21] was not detected here. In the presence of a few 
osmolytes (beta-alanine, TMAO, proline betaine) kinetics appeared to deviate from 
sigmoidal shape and gave rise to a steep increase from the start of the experiment. This was 
probably due to the instrument's upper limit of time resolution. Lag time, corresponding to 
the time where 5% of the maximum fluorescence had been reached, was used as an 
indicator of fibrillation velocity [21]. Since kinetics was strongly dependent on the added 
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fibril seed stock, each series of experiments included a triplicate control lacking osmolyte 
additive. All data within a series are presented as percentage of this control. 
Effect of osmolyte additives on fibrillation kinetics  
    When lag times were plotted vs. osmolyte concentration, an apparently linear increase 
was observed for compounds of the polyol group, while for the majority of the other 
compounds, a non-linear decrease was apparent. For consistency and comparability, all 
data were plotted as log (lag time) vs. concentration and subjected to linear regression 
(Figure 20). This did not affect coefficients of determination negatively even in the case of 
polyols (polyol average adjusted r
2
 = 0.935 for linear and adj. r
2
 = 0.937 for half-
logarithmic fits). The slope of the regression line was then used as a measure of kinetic 
stabilization potency of the respective compound. The variation of stabilization potency 
within osmolyte substance classes is described by the ratio of the highest and lowest 
observed concentration effect.  
Polyols slow down fibrillation 
    For all compounds of the polyol group, lag times increased with polyol concentration, 
indicative of a stabilizing effect (Figure 20A). Experiments were highly reproducible, as 
shown by error bars, and substantial variation of stabilization potency within this 
compound group was observed. Within the polyol group, the stabilization potency varied 
by a factor of 13.5 between myo-Inositol with the highest and glucose with the lowest 
effect.  
Amino acids and methylamines accelerate fibrillation 
    In contrast to polyols, most compounds of the amino acid and methylamine group 
decreased lag times, i.e. acted as kinetic destabilizers (Figure 20B and C). Beta-alanine and 
proline betaine were the strongest destabilizers in the amino acid and methylamine groups, 
respectively. Two compounds, namely COS and taurine, did not affect lag times 
significantly at any concentration measured. The destabilization potency of the other 
osmolytes varied by a factor of 3.4 for amino acids or 4.5 for methylamines, respectively. 
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Figure 20. Concentration-dependent effect of osmolytes on kinetic stability at pH 2.5. 
Half-logarithmic plot of lag times versus osmolyte concentration (A) Polyols, (B) amino 
acids, (C) methylamines. Slopes of regression lines represent kinetic stabilization potency 
of the respective osmolyte (see Table 10 in supplementary material for potency values, 
their errors and coefficients of determination). Destabilizing osmolytes show negative 
slopes. Error bars are included. Control lag time is always set as 100 %, which equals a 
value of 2 in a logarithmic transformation. 
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Effect of osmolyte additives on thermal stability 
    The determination of thermal stability is the most frequently used method to study the 
effects of osmolytes on protein stability, although it is not automatically related to 
aggregation kinetics. We therefore determined the influence of increasing osmolyte 
concentrations on the unfolding temperature (Tm) of lysozyme by differential scanning 
fluorimetry [27]. Solvents used were identical to those in the fibrillation model, i.e. all 
measurements were recorded at pH 2.5. The melting point of the osmolyte-lacking control 
was determined at 59.1 °C (± 0.2 °C). Thermal stabilization potency was determined by 
plotting log (Tm) vs. osmolyte concentration and calculating the slope of the regression line 
in analogy to the kinetic stabilization potency introduced above. As for the fibrillation 
experiments, logarithmically transformed data yielded the highest coefficients of 
determination. The relationship between Tm and osmolyte concentration was broadly 
similar to that between lag time and osmolyte concentration: polyols increased Tm in an 
apparently linear fashion, while most of the other compounds decreased Tm, and 
concentration dependence was nonlinear (Figure 21). However, when the compounds 
within substance groups were ranked according to their stabilization potency, compound-
specific differences between kinetic and thermal stabilization potency became obvious. 
Polyols increase Tm 
    Thermal stabilizing potency of polyols varied by a factor of 9.9 between the weakest and 
the strongest additive (Figure 21A). Glycerol, while among the best stabilizers in 
fibrillation experiments, appeared as the least potent polyol in Tm experiments. On the 
other hand, myo-inositol, which proved by far to be the best kinetic stabilizer, was less 
prominent in thermal stabilization where differences between compounds were generally 
much smaller.  
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Figure 21. Concentration-dependent effect of osmolytes on thermal stability at pH 2.5. 
Half-logarithmic plot of Tm vs. osmolyte concentration. (A) Polyols, (B) amino acids, (C) 
methylamines. Slopes of regression lines represent thermal stabilization potency of the 
respective osmolyte (see Table 10 in supplementary material for potency values, their 
errors and coefficients of determination). Destabilizing osmolytes show negative slopes. 
Error bars are included. Control melting point was measured at 59.1 °C (± 0.2 °C), which 
equals a value of 1.77 in a logarithmic transformation.  
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Amino acids and methylamines decrease Tm 
    In contrast to the stabilizing effect of polyols and similar to the results obtained in 
fibrillation experiments, addition of most amino acids and methylamines led to decreasing  
melting points (Figure 21B and C). For the class of amino acids, beta-alanine again had by 
far the highest impact, decreasing Tm by almost 4 °C at the highest concentration. Two 
osmolytes, namely hydroxyectoine and taurine, showed nearly no effect. In contrast to 
fibrillation experiments even a weak thermal stabilizer was found with glutamine.  
    Of the methylamine class, betaine was the least potent destabilizer, while proline betaine 
had the strongest (factor 7.0) destabilizing effect. COS, which did not affect lag times, led 
to a small decrease in Tm.  
    The destabilizing effect of amino acids and methylamines in both experiments may 
appear unexpected since osmolytes have generally been known to stabilize proteins. We 
hypothesized that our results could be caused by the low pH of 2.5 at which the 
experiments were conducted. In a second set of experiments, we therefore measured the 
effect of osmolytes on Tm at pH 7.0, buffered with 0.1 M sodium phosphate. Indeed, at 
neutral pH, we observed a stabilizing effect of almost all osmolytes as described earlier [5, 
6, 8], proline betaine being the only exception with a very low destabilizing effect (Figure 
22). As we haven't been able to develop a lysozyme fibrillation protocol at neutral pH yet, 
those Tm data could not be correlated with corresponding kinetic experiments, though. 
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Figure 22. Concentration-dependent effect of osmolytes on thermal stability at pH 7.0. 
Half-logarithmic plot of Tm vs. osmolyte concentration. (A) Polyols, (B) amino acids, (C) 
methylamines. Slopes of regression lines represent thermal stabilization potency of the 
respective osmolyte (see Table 11 in supplementary material for potency values, their 
errors and coefficients of determination). Error bars are included. Control melting point 
was measured at 69.5 °C (± 0.2 °C), which equals a value of 1.84 in a logarithmic 
transformation.  
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Osmolytes exhibit similar effects on thermal and kinetic stability. 
    To enable comparison of kinetic and thermodynamic stabilization potency, the slopes of 
Figure 20 and Figure 21 were normalized with respect to myo-Inositol for polyols, proline 
betaine for methylamines and beta-alanine for the amino acid group. In Figure 23, the 
normalized slopes of kinetic data are correlated with normalized slopes of Tm 
measurements. Both for stabilizing as well as for destabilizing compounds, a weak 
correlation between the two effects is evident (adj.  r
2
 = 0.59 for y = x). 
 
Figure 23. Correlation of kinetic and thermal stabilization potency. Slopes of the regression 
lines from Figure 20 and Figure 21 were normalized as described in the text, resulting in a 
value of 1/-1 for the osmolyte with the highest stabilization/destabilization potency within 
a substance class. Values from Tm measurements are plotted on the x-, those from 
fibrillation experiments on the y-axis. Fitting the curve to y=x gained an adj. r
2 
of 0.59. 
 
Molecular properties important for stabilization / destabilization 
    As a next step in our analysis, we attempted to identify molecular properties of the 
osmolytes that correlate with their effects on Tm or aggregation kinetics, respectively. 
Single and double linear regressions (the latter only for amino acids and methylamines) for 
kinetic and thermal stabilization potency vs. MW and pKa were performed (see Table 8, 
for MW and pKa values of compounds). pKa values were calculated from osmolyte 
structure using the software Marvin [28] as no other single source of pKa values for all 
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osmolytes was available. Stabilizing polyols were analyzed separately from the primarily 
destabilizing amino acid and methylamine group, as the mostly opposite effects make a 
common mechanism unlikely. Results are summarized in Table 9. Molecular weight has no 
significant influence on the effect of amino acids and methylamines, whereas a high pKa 
value strongly correlates with high destabilization potency. The impact of pKa values is 
more pronounced in fibrillation experiments. For the group of amino acids and 
methylamines, coefficients of determination are also higher in kinetic experiments. For the 
polyol group, we observe a correlation of MW and stabilization proficiency, but only in 
melting point experiments, where high MW polyols are more efficient in maintaining 
thermal stability (see also Figure 24 in supplementary material). 
Table 9: Osmolyte effect and molecule characteristics: Correlation of slopes with 
molecular weight (MW) and pKa value    
 Thermal 
stabilization potency 
Kinetic 
stabilization potency 
Regression 
coefficient 
x 10
-4 
adj. r
2
 
Regression 
coefficient 
x 10
-3
 
adj. r
2
 
Amino acids / 
methylamines 
DLR
1
MW 0.18 (± 2.5)  -8.6 (± 11)  
 pKa -76 (± 51) 0.08 -940 (± 230) 0.56 
SLR
2
MW 2.0 (± 2.2) -0.012 14 (± 15) -0.0011 
SLR
2
pKa -78 (± 42) 0.16 -850 (± 200) 0.58 
Polyols SLR
2 
MW 1.1 (± 0.54) 0.34 -0.33 (± 1.1) -0.18 
Values were obtained via 
1
 double linear regression or 
2
 single linear regression.  
Discussion 
    The effect of osmolytes on thermal stability of proteins and its underlying molecular 
mechanisms have been investigated by several authors in the past [4–6, 8, 9]. With respect 
to protection of proteins from aggregation, systematic work is less abundant. Published 
reports mostly deal with application-oriented case studies and a limited set of additives that 
reduce or slow down aggregation [12, 29-31]. In our present work, we examine a larger set 
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of osmolytes using a single test system of protein aggregation. We then directly compare 
thermal and kinetic stabilization propensities of osmolytes and tentatively correlate those 
properties to two selected structural features, MW and pKa. 
    Our main findings are: (i) thermal and kinetic stabilization correlate in general. (ii) 
However, there are significant deviations from this correlation making the prediction of 
aggregation inhibition from Tm measurements uncertain. These deviations are not caused 
by experimental noise, but instead significant as evidenced by error bars not reaching the 
diagonal. (iii) As a conclusion, compound-specific properties must significantly contribute 
to stabilization potency. Part of these molecule-specific effects can be attributed to 
molecular mass (increase of melting points with large polyols) and pKa value 
(destabilizing effect of zwitterionic compounds increases with pKa). (iv) Zwitterionic 
substances that increase Tm at neutral pH can decrease Tm at acidic pH. (v) Polyols 
enhance kinetic and thermal stability, the latter even more at low pH values than at neutral 
pH.   
     It is not too surprising that the correlation between thermal and kinetic stabilization is 
not perfect. Some aggregation mechanisms, including fibrillation investigated here, require 
at least partial unfolding or misfolding of the target protein to proceed [1]. However, the 
mechanisms destabilizing the native structure of a protein could also reduce their bias to 
aggregate. Well-known examples are urea or guanidinium, which lower Tm, i.e. promote 
unfolding, and inhibit aggregation [32, 33]. Both effects can be attributed to the chaotropic 
effect resulting in a weakening of hydrophobic interactions [34].  
    Thermal stability might therefore serve as an indicator for kinetic stability but cannot 
securely predict aggregation kinetics. A positive but also imperfect relationship between 
the osmolyte effect on melting points and aggregation kinetics was also found by Chen and 
Arakawa in a study on human keratinozyte growth factor [6]. They conclude that while 
thermal denaturation is a rate-limiting step in aggregation kinetics, additional direct 
interactions between osmolytes and protein must also contribute to a prolonged protein 
shelf life.   
    The effects of osmolytes on protein stability have been attributed to a combination of 
volume exclusion (preferential hydration) and preferential binding to the protein surface 
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[13, 14]. Volume exclusion is generally favouring the compact protein structure over a 
(partially) unfolded structure taking up more volume. The volume exclusion effect 
therefore always stabilizes folded proteins such as lysozyme. For natively unfolded 
proteins, e.g. glucagon, the same effect can promote the formation of aggregates as long as 
the aggregates are more compact than the soluble form [21 and references therein]. 
    For the polyol group, both a preferential binding to the native state as well as a volume 
exclusion effect seem possible, as all compounds act as stabilizers. However, the present 
data do not allow us to determine the dominating mechanism. As the volume exclusion 
effect should correlate with total volume taken up by the solute, we expected a positive 
correlation between stabilizing potency and molecular mass as previously shown for 
various sugar osmolytes [35]. However, only a small correlation was observed for thermal 
stability experiments, letting us conclude that molecule-specific effects surmount volume 
exclusion. This is especially true for the kinetic experiment, where stabilizing potency of 
four monosaccharides with the same MW differ over one order of magnitude. We also find 
an increase in polyol stabilization potential at low pH compared to neutral pH as observed 
before for various polyols e.g. trehalose, sorbitol or glycerol [16, 18]. This effect has been 
attributed to increased preferential exclusion of the osmolytes: As a protein gets more 
hydrophobic at low pH values due to protonation of COO
- 
groups [36], solvophobic 
interactions of the OH groups from protein and polyols occur [18].  
    Preferential binding on the other hand is generally associated with destabilization [13, 
14, 22, 37]. However, when binding to the native form exceeds binding to the denatured 
protein, a stabilizing effect is observed [19].  
    Since destabilization of globular proteins has only been reported with preferential 
binding so far, we suggest this as the underlying mechanism for the observed effects with 
most amino acids and methylamines. At our experimental pH, most of the amino acids and 
methylamines carry a net positive charge in contrast to neutral pH, were they are 
zwitterionic. Destabilizing properties can be related with osmolyte charge, as it was shown 
for TMAO [14, 38] and are partly explained by the perturbation of electrostatic interactions 
within a protein, hindering correct folding [38]. We find a positive correlation between 
pKa value and destabilization potential of osmolytes, and this correlation is most obvious 
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for compounds where the pKa lies far away from pH 2.5. Examples are TMAO with a high 
and taurine with a low destabilizing effect, corresponding to high or low pKa values, 
respectively. For compounds with a pKa value close to the experimental pH this 
relationship is less visible, possibly due to small errors in calculating the predicted pKa 
leading to large differences between predicted and actual charge of the molecule at pH 2.5. 
Direct electrostatic attraction between osmolyte and lysozyme might however not be the 
dominating interaction leading to preferential binding, as not only the compounds, but also 
the protein are positively charged at pH 2.5. Concerning amino acids and apart from our 
recent study on osmolyte impact on glucagon fibrillation [21], we are not aware of 
publications having witnessed low stability in the presence of this osmolyte group at low 
pH. In fact the opposite was reported, as Taneja et al. observed a thermally stabilizing 
effect for moderately hydrophobic amino acids at pH 3.0 [4].  
    A more detailed understanding of osmolyte action on aggregate formation will require 
both molecular understanding of the aggregation mechanism as well as of the specific 
interaction of solute and protein surface. More model systems allowing controlled 
formation of different types of aggregates and even larger sets of stabilizers will be 
required to extract information that could be useful in designing novel molecules that 
surpass the stabilizing properties of naturally occurring osmolytes.  
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Supplementary Materials 
 
 
Figure 24. Correlation of stabilization potency with molecule characteristics at pH 2.5. Plot 
of pKa value (A) and molecular weight (B) (x-axis) vs. stabilization potency (y-axes). As 
they generally share a destabilizing effect, results from the amino acids and methylamines 
group are combined in (A), where a high pKa value is associated with higher 
destabilization potential. The experimental pH of 2.5 is marked as X on the x-axis. In (B), 
showing results for polyols, the regression of molecular weight with stabilization potency 
is only significant in thermal experiments. No diagram is shown relating molecular weight 
of amino acids and methylamines, as the correlation was not significant in both 
experiments.  
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Table 10: Comparison of concentration-dependent osmolyte effect in thermal and kinetic 
experiments at pH 2.5 
 
 Thermal stabilization 
potency 
Kinetic stabilization 
potency 
Regression 
coefficient  
× 10
-2 
adj. r
2
 
Regression 
coefficient  
× 10
-2
 
adj. r
2
 
Polyols Trehalose 3.5 (± 0.13) 0.98 30 (± 1.2) 0.98 
Mannitol 3.6 (± 0.10) 0.99 48 (± 1.4) 0.99 
Sorbitol 2.4 (± 0.10) 0.99 21 (± 1.0) 0.97 
Erythritol 1.4 (± 0.03) 0.99 45 (± 2.3) 0.97 
Glucose 2.4 (± 0.07) 0.99 7.6 (± 1.5) 0.69 
Glycerol 0.42 (± 0.10) 0.54 34 (± 1.1) 0.99 
Myo-Inositol 4.0 (± 0.09) 1.0 67 (± 3.5) 0.97 
Amino acids 
and 
derivatives 
Proline -3.2 (± 0.40) 0.85 -120 (± 19) 0.79 
Serine -2.4 (± 0.21) 0.92 -250 (± 15) 0.96 
Glycine -2.9 (± 0.55) 0.71 -410 (± 12) 0.99 
Taurine 0.54 (± 0.15) 0.54 1.4 (± 4.0) -0.09 
Ectoine -4.0 (± 0.32) 0.94 -260 (± 27) 0.89 
Hydroxyectoine 0.69 (± 0.24) 0.41 -250 (± 32) 0.85 
Glutamine 2.5 (± 0.72) 0.51 -420 (± 11) 0.99 
Alanine -1.8 (± 0.26) 0.80 -190 (± 7.9) 0.98 
Beta-Alanine -5.6 (± 0.92) 0.77 -570 (± 8.0) 0.82 
Methyl-
amines 
Betaine -1.3 (± 0.33) 0.58 -120 (± 13) 0.89 
COS -1.1 (± 0.16) 0.80 5.7 (± 3.7) 0.12 
TMAO -5.7 (± 0.86) 0.80 -530 (± 23) 0.98 
Proline Betaine -7.8 (± 1.2) 0.79 -540(± 43) 0.93 
Sarcosine -5.7 (± 0.52) 0.92 -320 (± 15) 0.98 
 
 
Publications & Manuscripts  88 
 
 
Table 11: Concentration-dependent osmolyte effect in thermal experiments at pH 7.0 
 
 Thermal stabilization potency 
Regression 
coefficient 
× 10
-2 
adj. r
2
 
Polyols Trehalose 2.7 (± 0.07) 0.99 
Mannitol 1.8 (± 0.14) 0.94 
Sorbitol 2.0 (± 0.15) 0.94 
Erythritol 1.0 (± 0.05) 0.98 
Glucose 1.3 (± 0.15) 0.87 
Glycerol 0.36 (± 0.04) 0.87 
Myo-Inositol 2.4 (± 0.19) 0.94 
Amino acids 
and 
derivatives 
Proline 2.3 (± 0.31) 0.83 
Serine 3.3 (± 0.31) 0.91 
Glycine 3.4 (± 0.29) 0.93 
Taurine 3.5 (± 0.33) 0.91 
Ectoine 1.4 (± 0.20) 0.80 
Hydroxyectoine 2.5 (± 0.24) 0.90 
Glutamine 1.5 (± 0.22) 0.80 
Alanine 3.4 (± 0.18) 0.97 
Beta-Alanine 2.0 (± 0.48) 0.61 
Methylamines Betaine 1.8 (± 0.22) 0.85 
COS 0.17 (± 0.19) -0.02 
TMAO 2.7 (± 0.23) 0.93 
Proline Betaine -0.40 (± 0.30) 0.07 
Sarcosine 3.5 (± 0.30) 0.92 
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6 
Summary 
 
Pharmaceutical proteins constitute an important class of products in the biotech industry. 
Among them, monoclonal antibodies have become a driven force for the growth of the 
whole market, because of their broad application in clinical diagnostics and therapeutics. 
For the recovery of these products from fermentation broths, several preparative modes of 
chromatography are employed. Some of them, such as protein A chromatography, are 
costly and have limited scalability. The present thesis explores the possibility to implement 
crystallization, which is one of the oldest purification techniques used in chemical 
technology, in the early downstream process. Chapter 3 focuses on exploring the phase 
diagram of a monoclonal antibody to identify optimized crystallization conditions with 
regard to yield and purity. Chapter 4 is concerned with analyzing the impact of 
contaminating proteins on the crystallization process. Chapter 5 deals with the competing 
process of protein aggregation, which can prevent crystallization if not controlled by the 
addition of stabilizers. A lysozyme fibrillation model system was used to test a set of 
naturally occurring osmolytes for their stabilizing potency.  
     The successful development of crystallization as a purification step for a monoclonal 
antibody presented in Chapter 3 shows that crystallization has the potential to be 
introduced as a purification step for mAbs. After identifying crystallization conditions, 
protein solubility was studied as a function of the concentration of target protein 
BImAb04c and of the precipitant PEG. The solubility limit in this system was determined 
by preparing saturated solution in equilibrium with crystalline protein and measuring the 
protein concentration in the supernatant. By applying the resulting phase diagram, batch 
crystallization could be performed and scaled by carefully choosing operation conditions in 
the metastabile zone. In spiking experiments, BImAb04c could be crystallized in the 
presence of lysozyme or BSA. Analysis of crystallization samples by SDS-PAGE after 
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crystallization indicated that most of the spiking proteins were excluded from the crystals. 
In further experiments, crystallization conditions were adapted to crystallize the antibody 
directly from concentrated clarified cell culture supernatant. As a result, BImAb04c 
achieved a purity of more than 90% in a single crystallization step at small scale. In 
addition, aggregate formation was negligible during the whole process. But with a low 
recovery rate of about 30 % even after 5 days of incubation time, crystallization cannot 
compete with the widely-used protein A chromatography as a capturing step. Still, it was 
shown in this chapter that protein crystallization has the potential to be introduced as a 
purification step for mAbs, but more likely as a later purification step and not for 
capturing. 
     It is known from crystallography that the presence of impurities is a critical problem, 
since impurities may incorporate into growing protein crystals and thus affect defect 
densities, morphology and diffraction resolution of crystals. For bulk protein 
crystallization, crystal growth rate is more relevant than crystal diffraction quality. In 
Chapter 3, it was demonstrated that the presence of protein impurities in fermentation 
broth slowed down crystallization process of BImAb04c significantly. In Chapter 4, 
crystallization of mAb04c was conducted in the presence of various model contaminant 
proteins. Spiking test with BSA indicated that the reduction of the crystallization rate 
correlated with the molar ratio of impurity to target protein. This could be expected, as 
protein impurities can bind to active growth site of the crystal and prevent the target 
protein from becoming incorporated into the crystal. This inhibition is likely to depend on 
the impurity concentration. Another spiking protein ovalbumin showed the similar 
inhibition as BSA. Meanwhile, two other spiking proteins, lysozyme and cytochrome c, did 
not inhibit crystallization at concentrations comparable to BSA and ovalbumin. CG-MALS 
experiments supported the view that this difference was probably due to different types of 
interaction (attractive vs. repulsive) between protein impurity and target. In the low ionic 
strength system tested here, electrostatic interactions would be sufficient to explain the 
observed differences. Although other interactions might become dominant under different 
crystallization conditions, this indicates that analysis of molecular interactions in solution 
might help to predict inhibitory effects of specific contaminants and design process steps 
that improve crystallization rate and yield. Here, an anion exchange chromatography 
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operated in flow-through mode preceding crystallization should improve the crystallization 
efficiency and raise the product yield.  
     Maintaining stability is a major issue during the production of biopharmaceuticals, 
because aggregation results in activity loss and immunogenic adverse reactions. In case of 
protein crystallization, amorphous aggregates compete with the formation of crystals. For 
these reasons, aggregation is to be avoided at all costs. Therefore, stabilization potency of 
different osmolytes classes (polyols, amino acids and methylamine groups) was examined 
additionally in Chapter 5, focusing on lysozyme as an example of a folded globular 
protein. In measuring melting points with differential scanning fluorimetry and aggregation 
kinetics (model system fibrillation) using the fluorescent dye thioflavin T, osmolyte effects 
are related to molecule characteristics and a possible connection between thermal stability 
and kinetic stability was investigated. It was found that polyols increased both thermal and 
kinetic stability in a concentration-dependent manner, whereas most compounds from the 
amino acids and methylamine groups led to destabilization. The latter can possibly be 
ascribed to charge-related preferential binding mechanisms, as the strength of impact is 
related to increasing compound pKa values and stabilizing effects of these osmolytes near 
neutral pH. Furthermore, it was observed that there was similar but not identical effects of 
particular osmolytes on both types of stability. Thus, kinetic stability cannot solely be 
predicted by melting points, which is used to measure thermal stability of proteins. This 
kind of analysis could be helpful for aggregation control and thereby, benefits protein 
crystallization. 
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Appendix 
Experimental methods 
 
1. Crystallization through vapor diffusion 
Vapor diffusion is the most widely used approach for screening of crystallization 
conditions at present. The detailed mechanism of this method is discussed in Chapter 
2.1.2. Two common procedures are involved in this method, and they are sitting-drop and 
hanging drop vapor diffusion, named according to position of sample droplet. 
a. Hanging-drop crystallization 
The 24 well crystallization plates (24 Well ComboPlate™, Greiner Bio-one, Germany) 
were applied for hanging-drop crystallization. Volume of 1 ml crystallization reagent was 
pipetted into reservoir of plate. A bead of vacuum grease (Bayer, Germany) was applied 
along the upper edge of the reservoir. Subsequently, 1-2 µl protein solution was mixed 
with an equivalent volume of crystallization reagent in the center of a siliconized 18 mm 
circle cover slide (Jena Bioscience, Germany). The cover slide was then inverted so the 
droplet if hanging from the cover slide, positioned and pressed gently down onto the bead 
of grease on the reservoir to keep it tight.     
b. Sitting-drop crystallization  
Sitting-drop crystallization was performed either directly in 96 well crystallization plate 
from Corning, USA, or 24 well ComboPlate™ with help of Crystalbridge™ (Greiner Bio-
one, Germany). With a 96 well crystallization plate, volume of 100 µl crystallization 
reagent was pipetted into reservoir (large well of the plate). 1-1.5 µl protein solution was 
mixed with 1-1.5 µl crystallization reagent in the small well of plate. All reservoirs were 
then sealed with clear plate sealing tape (Greiner VIEWseal, Greiner Bio-one) after 
preparation. In the case of 24 well ComboPlate volume of 1 ml reagent was transferred into 
reservoir. A Crystalbridge was placed into the bottom of reservoir. Droplet (maximum 40 
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µl) composed of protein solution and crystallization reagent was prepared in the concave 
depression of the Crystalbridge. Reservoir was then sealed with glass cover slide. 
2. Microbatch crystallization under Oil 
Batch technique is a simple and one of the oldest crystallization techniques. In labor, 
microbatch (with a volume less than 10 µl) is commonly performed under paraffin oil, to 
prevent aqueous samples from evaporation. The 60 well Terasaki plate was employed for 
performance of microbatch crystallization. A volume of 5-6 ml 100 % paraffin oil 
(Hampton research, USA) was pipetted into a Terasaki plate. Droplet (up to 10 µl) 
composed of protein solution and crystallization reagent was then mixed in the cone-shape 
depression in the microbatch plate. Plate cover was finally placed over plate to prevent 
dust from entering experiment.      
3. Seeding Techniques  
Seeding is a technique widely applied in protein crystallization. Crystal from primary 
crystallization can be seeded in the new crystallization drop or batch, to improve quality 
and growth rate of crystals, or distinguish microcrystalline from amorphous precipitate 
during screening. Seeding can be homogeneous or heterogeneous, depending on whether 
the seeds are composed of the same components as the target protein or not. This work 
deals mostly with the homogeneous seeding. Streak seeding and microseeding are two 
most popular seeding approaches and were employed in this work.  
a. Streak seeding    
Streak seeding (Figure 25) was mainly used for the screening of crystal-growth conditions 
or to diagnostic to confirm whether phase separation or amorphous precipitate is 
crystalline. Seeding Tool made of nature fiber (HR8-133, Hampton Research) was inserted 
into droplet and was dragged through microcrystalline or crushed crystal so that seed 
crystals could attached to the fiber. A straight line was drawn with the fiber across a fresh 
crystallization drop containing the protein sample and reagent adequate to support growth. 
Crystals appear along the streak line, if the streak seeding has been successful.     
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Figure 25. Schematic representation of the procedure for streak seeding. Crystal seed will 
be transported to a fresh crystallization drop with help of a probe made of nature fiber. 
New crystals can grow from these seeds if the conditions in droplet are suitable.  
b. Microseeding in solution 
Microseeding, illustrated in Figure 26, was used to introduce a controlled number of 
crystal seeds into fresh mother liquor. Crystals were separated from the mother liquor by 
10 min centrifugation at 4 °C and 10,000g and washed 3 times with reservoir solution, 
each volume of the wash reservoir being the same as that of the original sample of crystal 
suspension. The crystal suspension was then transferred into a microcentrifuge tube 
containing a Teflon Seed Bead™ (Hampton Research). Through vortex, a homogeneous 
stock solution of microseeds was generated with help of the bead. A series of dilutions 
were then performed to establish an appropriate dilution for Microseeding.  
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Figure 26. Schematic representation of microseeding method. A homogeneous stock 
solution of microseeds is generated by a Teflon bead. After a series of dilution, a 
controlled number of microcrystals are seeded in fresh mother liquor after a series of 
dilution.   
  
4. Analyzing protein-protein interaction via static light scattering 
The osmotic second virial coefficient A2 is used to characterize overall protein-protein self 
interactions in one protein system, which is contributed by electrostatics, van der Waals 
interactions, excluded volumes, hydration forces, and hydrophobic effects. Similarly, the 
osmotic second cross virial coefficient A11 can also be employed to suggest cross 
interactions in multi-protein system. Through transformation of Equation (2) in Chapter 
2.2.2, the virial coefficient for a single species in dilute solution can be expressed as: 
 
 
Therefore, determination of the A2 consists of measurement of the excess Rayleigh ratio 
R(?) over several values of protein concentration c, construction of Zimm plot, and fitting 
the data. Likewise, the second cross virial coefficient A11 of a two-protein system may be 
determined by measuring R(?) at a series of compositions of the two soluble proteins A 
and B—changing the ratio c
A
:c
B
—and fitting the results to following equation (Some D, et 
al. 2009):      
???????? ? ?????????????? ???????                                                  (8) 
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The determination of virial coefficient is a time-consuming and tedious process if carried 
out manually. In this work, an automated composition-gradient multiangle static light 
scattering (CG-MALS) was employed for the characterization of the A2 and A11 in 
solution. The whole system (Figure 27) includes an automated composition gradient 
system (Calypso™ II), a static light scattering instrument (Dawn®-8), and a differential 
refractive index detector (Optilab® T-rEX). All the instruments are from Wyatt 
Technology, USA. 
 
 
Figure 27. The CG-MALS system composed of a composition gradient pump system, a 
static light scattering detector and a concentration detector. Solid lines indicate fluid 
connections. Dashed lines indicate electrical connections.   
 
RI detector 
MALS detector 
Calypso System 
Waste 
?????? ? ????????????????????????? ????????????????????????               (9)   ????? ??????? ??????????????????????  
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     The Calypso system is an automated composition delivery system composed of three 
computer controlled syringe pumps linked to reservoirs. The pumps are operated separately 
through control software. Therefore, up to three solutions can be mixed by pumping 
through a static mixer and achieve then different compositions. Since light scattering 
detector is very sensitive to large particles, in-line filter (0.1 µm, Millipore, US), is 
assembled after each pump to prevent large aggregates and particles, which are generated 
by mechanical motion of syringes and valves, from disturbing light scattering signals.    
     A multiangle light scattering (Dawn-8) was employed for the measurement of scattered 
light intensity of particles in different angle. The laser wavelength is 658 nm. The detector 
has photodiode detectors at eight scattering angles, ranged from 23°-155°, and scattering 
volume of 0.07 µl.  
     The Optilab T-rEX differential refractive index (RI) detector was served as online 
concentration detector. The refractive index of solution is related to concentration of the 
solute. Therefore, knowing the slope of the dependence of refractive index of protein 
solution on its concentration, i.e. the dn/dc value, concentration of protein can be 
determined. For most proteins in aqueous buffers the dn/dc is 0.185 mL/g, which is an 
advantage of RI detector compared to UV detector, since determination of extinction 
coefficient of protein is not required. The RI detector has a flow cell separated into two 
parts, that is, the reference cell and the sample cell. Both parts were flushed with reference 
fluid (running buffer) before the experiments. The reference cell was closed, when baseline 
stayed constant. Fluid was then directed through the sample cell. Any differences of RI 
between the two cells lead to change of signal peak area. To obtain accurate concentration 
data, protein solutions were dialyzed against the running buffer used in the experiment 
sufficiently, well-degassed and filtrated through 0.2 µm syringe filter (Sartorius, Germany). 
5. Determination of protein melting points with the LightCycler 480 
Protein melting points was determined with a Roche LightCycler 480 using SYPRO 
Orange (5000× in DMSO, Invitrogen, Germany) as fluorescence dye. With increased 
temperature, proteins exhibit unfolding and expose their hydrophobic regions, which can 
interact with SYPRO Orange in solution. The fluorescence signal rises then with an 
increase of the exposed hydrophobic regions.  
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     In a reaction volume of 50 µl, a final concentration of 0.8 mg/ml lysozyme was mixed 
with varying osmolyte concentrations in 96 well LightCycler plates (white, opaque). 
SYPRO Orange was diluted 1000 fold in each assay. The plates was then sealed with clear 
plate sealing tape (Greiner VIEWseal, Greiner Bio-one) and shaken for 1 min at 400 rpm. 
Change of fluorescence signal was monitored (excitation 483nm, emission 568 nm) by 
LightCycler with increased temperature. Melting points were derived from the inflexion 
point of the melting curves. All experiments were carried out in triplicates 
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